Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3663882,AUC,"The mean 48-h AUC values were 240.7 and 231.3 h X ng ml-1 for the conventional and CR tablets, respectively, while the corresponding Cmax values ranged from 5.3 to 6.8 ng ml-1 and 5.4 to 6.5 ng ml-1.",Comparative steady state bioavailability of conventional and controlled-release formulations of albuterol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663882/),[h·ng] / [ml],240.7,1023,DB01001,Salbutamol
,3663882,AUC,"The mean 48-h AUC values were 240.7 and 231.3 h X ng ml-1 for the conventional and CR tablets, respectively, while the corresponding Cmax values ranged from 5.3 to 6.8 ng ml-1 and 5.4 to 6.5 ng ml-1.",Comparative steady state bioavailability of conventional and controlled-release formulations of albuterol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663882/),[h·ng] / [ml],231.3,1024,DB01001,Salbutamol
,3663882,Cmax,"The mean 48-h AUC values were 240.7 and 231.3 h X ng ml-1 for the conventional and CR tablets, respectively, while the corresponding Cmax values ranged from 5.3 to 6.8 ng ml-1 and 5.4 to 6.5 ng ml-1.",Comparative steady state bioavailability of conventional and controlled-release formulations of albuterol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663882/),[ng] / [ml],5.3 to 6.8,1025,DB01001,Salbutamol
,3663882,Cmax,"The mean 48-h AUC values were 240.7 and 231.3 h X ng ml-1 for the conventional and CR tablets, respectively, while the corresponding Cmax values ranged from 5.3 to 6.8 ng ml-1 and 5.4 to 6.5 ng ml-1.",Comparative steady state bioavailability of conventional and controlled-release formulations of albuterol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663882/),[ng] / [ml],5.4 to 6.5,1026,DB01001,Salbutamol
,3663882,Cmin,"Cmin values ranged from 3.8 to 4.3 ng ml-1 and 3.0 to 4.8 ng ml-1 for the conventional and CR tablets, respectively.",Comparative steady state bioavailability of conventional and controlled-release formulations of albuterol. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663882/),[ng] / [ml],3.8 to 4.3,1027,DB01001,Salbutamol
,3663882,Cmin,"Cmin values ranged from 3.8 to 4.3 ng ml-1 and 3.0 to 4.8 ng ml-1 for the conventional and CR tablets, respectively.",Comparative steady state bioavailability of conventional and controlled-release formulations of albuterol. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663882/),[ng] / [ml],3.0 to 4.8,1028,DB01001,Salbutamol
,11145228,KaGI,"Mean population PK parameters were KaGI (10+/-5.7 h(-1)), KaLUNG (21+/-9.5 h(-1)), CLc/F (0.6+/-0.2 L/h/kg), CLd/F (1.4+/-0.5 L/h/kg), Vc/F (1.4+/-0.9 L/kg), and Vp/F (4.8+/-2.4 L/kg).",A population analysis of nebulized (R)-albuterol in dogs using a novel mixed gut-lung absorption PK-PD model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145228/),1/[h],10,2075,DB01001,Salbutamol
,11145228,KaLUNG,"Mean population PK parameters were KaGI (10+/-5.7 h(-1)), KaLUNG (21+/-9.5 h(-1)), CLc/F (0.6+/-0.2 L/h/kg), CLd/F (1.4+/-0.5 L/h/kg), Vc/F (1.4+/-0.9 L/kg), and Vp/F (4.8+/-2.4 L/kg).",A population analysis of nebulized (R)-albuterol in dogs using a novel mixed gut-lung absorption PK-PD model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145228/),1/[h],21,2076,DB01001,Salbutamol
,11145228,CLc/F,"Mean population PK parameters were KaGI (10+/-5.7 h(-1)), KaLUNG (21+/-9.5 h(-1)), CLc/F (0.6+/-0.2 L/h/kg), CLd/F (1.4+/-0.5 L/h/kg), Vc/F (1.4+/-0.9 L/kg), and Vp/F (4.8+/-2.4 L/kg).",A population analysis of nebulized (R)-albuterol in dogs using a novel mixed gut-lung absorption PK-PD model. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145228/),[l] / [h·kg],0.6,2077,DB01001,Salbutamol
,11145228,CLd/F,"Mean population PK parameters were KaGI (10+/-5.7 h(-1)), KaLUNG (21+/-9.5 h(-1)), CLc/F (0.6+/-0.2 L/h/kg), CLd/F (1.4+/-0.5 L/h/kg), Vc/F (1.4+/-0.9 L/kg), and Vp/F (4.8+/-2.4 L/kg).",A population analysis of nebulized (R)-albuterol in dogs using a novel mixed gut-lung absorption PK-PD model. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145228/),[l] / [h·kg],1.4,2078,DB01001,Salbutamol
,11145228,Vc/F,"Mean population PK parameters were KaGI (10+/-5.7 h(-1)), KaLUNG (21+/-9.5 h(-1)), CLc/F (0.6+/-0.2 L/h/kg), CLd/F (1.4+/-0.5 L/h/kg), Vc/F (1.4+/-0.9 L/kg), and Vp/F (4.8+/-2.4 L/kg).",A population analysis of nebulized (R)-albuterol in dogs using a novel mixed gut-lung absorption PK-PD model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145228/),[l] / [kg],1.4,2079,DB01001,Salbutamol
,11145228,Vp/F,"Mean population PK parameters were KaGI (10+/-5.7 h(-1)), KaLUNG (21+/-9.5 h(-1)), CLc/F (0.6+/-0.2 L/h/kg), CLd/F (1.4+/-0.5 L/h/kg), Vc/F (1.4+/-0.9 L/kg), and Vp/F (4.8+/-2.4 L/kg).",A population analysis of nebulized (R)-albuterol in dogs using a novel mixed gut-lung absorption PK-PD model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145228/),[l] / [kg],4.8,2080,DB01001,Salbutamol
,9853977,Cmax,"The mean Cmax and tmax for two CR tablets given after a single dose were 7.3+/-1.5, 7.9+/-1.4 microg x L(-1) and 4.6+/-0.8, 4.8+/-0.5 hours, respectively.",Relative biologic availability and pharmacokinetics of albuterol preparations in healthy Chinese. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853977/),[μg] / [l],7.3,4655,DB01001,Salbutamol
,9853977,tmax,"The mean Cmax and tmax for two CR tablets given after a single dose were 7.3+/-1.5, 7.9+/-1.4 microg x L(-1) and 4.6+/-0.8, 4.8+/-0.5 hours, respectively.",Relative biologic availability and pharmacokinetics of albuterol preparations in healthy Chinese. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853977/),[μg] / [l],7.9,4656,DB01001,Salbutamol
,9853977,tmax,"The mean Cmax and tmax for two CR tablets given after a single dose were 7.3+/-1.5, 7.9+/-1.4 microg x L(-1) and 4.6+/-0.8, 4.8+/-0.5 hours, respectively.",Relative biologic availability and pharmacokinetics of albuterol preparations in healthy Chinese. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853977/),h,4.6,4657,DB01001,Salbutamol
,9853977,tmax,"The mean Cmax and tmax for two CR tablets given after a single dose were 7.3+/-1.5, 7.9+/-1.4 microg x L(-1) and 4.6+/-0.8, 4.8+/-0.5 hours, respectively.",Relative biologic availability and pharmacokinetics of albuterol preparations in healthy Chinese. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853977/),h,4.8,4658,DB01001,Salbutamol
,9853977,Cmax,"The Cmax and tmax for two IR tablets given after a single dose were 12.5-/+1.3, 15.3 +/-2.3 microg x L(-1) and 1.3+/-0.4, 1.6+/-0.4 hours, respectively.",Relative biologic availability and pharmacokinetics of albuterol preparations in healthy Chinese. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853977/),[μg] / [l],12.5,4659,DB01001,Salbutamol
,9853977,tmax,"The Cmax and tmax for two IR tablets given after a single dose were 12.5-/+1.3, 15.3 +/-2.3 microg x L(-1) and 1.3+/-0.4, 1.6+/-0.4 hours, respectively.",Relative biologic availability and pharmacokinetics of albuterol preparations in healthy Chinese. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853977/),[μg] / [l],15.3,4660,DB01001,Salbutamol
,9853977,tmax,"The Cmax and tmax for two IR tablets given after a single dose were 12.5-/+1.3, 15.3 +/-2.3 microg x L(-1) and 1.3+/-0.4, 1.6+/-0.4 hours, respectively.",Relative biologic availability and pharmacokinetics of albuterol preparations in healthy Chinese. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853977/),h,1.3,4661,DB01001,Salbutamol
,9853977,tmax,"The Cmax and tmax for two IR tablets given after a single dose were 12.5-/+1.3, 15.3 +/-2.3 microg x L(-1) and 1.3+/-0.4, 1.6+/-0.4 hours, respectively.",Relative biologic availability and pharmacokinetics of albuterol preparations in healthy Chinese. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853977/),h,1.6,4662,DB01001,Salbutamol
,9853977,relative biologic availability,"The relative biologic availability of two CR albuterol tablets were 106.0+/-6.2% and 109.8+/-9.0%, respectively.",Relative biologic availability and pharmacokinetics of albuterol preparations in healthy Chinese. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853977/),%,106.0,4663,DB01001,Salbutamol
,9853977,relative biologic availability,"The relative biologic availability of two CR albuterol tablets were 106.0+/-6.2% and 109.8+/-9.0%, respectively.",Relative biologic availability and pharmacokinetics of albuterol preparations in healthy Chinese. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853977/),%,109.8,4664,DB01001,Salbutamol
,8458877,Cmax,"The Cmax following rectal administration was 17.9 ng/ml (17.0 ng/ml for oral administration), the tmax 0.67 h (1.5 h for oral administration) and the AUC 98.2 ng/ml/h (100 ng/ml/h for oral administration).",Serum concentration and cardiovascular effects of salbutamol after oral and rectal administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8458877/),[ng] / [ml],17.9,7532,DB01001,Salbutamol
,8458877,Cmax,"The Cmax following rectal administration was 17.9 ng/ml (17.0 ng/ml for oral administration), the tmax 0.67 h (1.5 h for oral administration) and the AUC 98.2 ng/ml/h (100 ng/ml/h for oral administration).",Serum concentration and cardiovascular effects of salbutamol after oral and rectal administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8458877/),[ng] / [ml],17.0,7533,DB01001,Salbutamol
,8458877,tmax,"The Cmax following rectal administration was 17.9 ng/ml (17.0 ng/ml for oral administration), the tmax 0.67 h (1.5 h for oral administration) and the AUC 98.2 ng/ml/h (100 ng/ml/h for oral administration).",Serum concentration and cardiovascular effects of salbutamol after oral and rectal administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8458877/),h,0.67,7534,DB01001,Salbutamol
,8458877,tmax,"The Cmax following rectal administration was 17.9 ng/ml (17.0 ng/ml for oral administration), the tmax 0.67 h (1.5 h for oral administration) and the AUC 98.2 ng/ml/h (100 ng/ml/h for oral administration).",Serum concentration and cardiovascular effects of salbutamol after oral and rectal administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8458877/),h,1.5,7535,DB01001,Salbutamol
,8458877,AUC,"The Cmax following rectal administration was 17.9 ng/ml (17.0 ng/ml for oral administration), the tmax 0.67 h (1.5 h for oral administration) and the AUC 98.2 ng/ml/h (100 ng/ml/h for oral administration).",Serum concentration and cardiovascular effects of salbutamol after oral and rectal administration in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8458877/),[ng] / [h·ml],98.2,7536,DB01001,Salbutamol
,15761945,peak concentrations,"Mean peak concentrations in healthy volunteers (six males and six females) were 1.74 +/- 0.34, 2.01 +/- 0.35, and 2.59 +/- 0.27 ng/mL following inhalation of formulations with fine particle doses (FPDs) of 100, 120, and 160 microg of albuterol, respectively.",The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761945/),[ng] / [ml],1.74,8450,DB01001,Salbutamol
,15761945,peak concentrations,"Mean peak concentrations in healthy volunteers (six males and six females) were 1.74 +/- 0.34, 2.01 +/- 0.35, and 2.59 +/- 0.27 ng/mL following inhalation of formulations with fine particle doses (FPDs) of 100, 120, and 160 microg of albuterol, respectively.",The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761945/),[ng] / [ml],2.01,8451,DB01001,Salbutamol
,15761945,peak concentrations,"Mean peak concentrations in healthy volunteers (six males and six females) were 1.74 +/- 0.34, 2.01 +/- 0.35, and 2.59 +/- 0.27 ng/mL following inhalation of formulations with fine particle doses (FPDs) of 100, 120, and 160 microg of albuterol, respectively.",The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761945/),[ng] / [ml],2.59,8452,DB01001,Salbutamol
,15761945,peak plasma concentrations,"The corresponding peak plasma concentrations of 1.23 +/- 0.29, 1.37 +/- 0.13, and 1.53 +/- 0.11 ng/mL were obtained when asthmatics (six males and six females) were dosed with the same three formulations.",The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761945/),[ng] / [ml],1.23,8453,DB01001,Salbutamol
,15761945,peak plasma concentrations,"The corresponding peak plasma concentrations of 1.23 +/- 0.29, 1.37 +/- 0.13, and 1.53 +/- 0.11 ng/mL were obtained when asthmatics (six males and six females) were dosed with the same three formulations.",The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761945/),[ng] / [ml],1.37,8454,DB01001,Salbutamol
,15761945,peak plasma concentrations,"The corresponding peak plasma concentrations of 1.23 +/- 0.29, 1.37 +/- 0.13, and 1.53 +/- 0.11 ng/mL were obtained when asthmatics (six males and six females) were dosed with the same three formulations.",The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761945/),[ng] / [ml],1.53,8455,DB01001,Salbutamol
,2376428,peak concentration,"The peak concentration of dextrorphan was achieved at 1.5 h after Extuson and at 2 h after Redol comp (1,053.0 +/- 366.5 ng/ml and 901.5 +/- 210.9 ng/ml, NS).",Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376428/),[ng] / [ml],"1,053.0",10895,DB01001,Salbutamol
,2376428,peak concentration,"The peak concentration of dextrorphan was achieved at 1.5 h after Extuson and at 2 h after Redol comp (1,053.0 +/- 366.5 ng/ml and 901.5 +/- 210.9 ng/ml, NS).",Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376428/),[ng] / [ml],901.5,10896,DB01001,Salbutamol
,2376428,AUC0-12,"AUC0-12 values of dextrorphan were 4,315.6 +/- 295.0 (ng/ml)h after Extuson and 3,983.8 +/- 205.6 (ng/ml)h after Redol comp (p less than 0.05).",Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376428/),h,"4,315.6",10897,DB01001,Salbutamol
,2376428,AUC0-12,"AUC0-12 values of dextrorphan were 4,315.6 +/- 295.0 (ng/ml)h after Extuson and 3,983.8 +/- 205.6 (ng/ml)h after Redol comp (p less than 0.05).",Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376428/),h,"3,983.8",10898,DB01001,Salbutamol
,2376428,peak concentration,Salbutamol was well absorbed from the combined preparation and the peak concentration was achieved at 3 h (6.57 +/- 2.95 ng/ml).,Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376428/),[ng] / [ml],6.57,10899,DB01001,Salbutamol
,1761082,Cmax,In 8 patients the single dose mean Cmax was 4.2 ng.,Pharmacokinetics of oral salbutamol controlled-release in Asian patients with asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761082/),ng,4.2,16021,DB01001,Salbutamol
,1761082,steady state mean Cmax,"In 5 patients the steady state mean Cmax, Cmin and tmax were 8.1 ng.",Pharmacokinetics of oral salbutamol controlled-release in Asian patients with asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761082/),ng,8.1,16022,DB01001,Salbutamol
,12579942,recoveries,The recoveries were between 90% and 110%.,[Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579942/),%,90,16470,DB01001,Salbutamol
,12579942,recoveries,The recoveries were between 90% and 110%.,[Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579942/),%,110,16471,DB01001,Salbutamol
,12579942,Tmax,"The pharmacokinetics of salbutamol aersol was described well with a two-compartment model, and the parameters for salbutamol inhaled and orally administered were assessed as follows: Tmax were (0.22 +/- 0.07) h and (1.8 +/- 0.6) h, Cmax were (3.4 +/- 1.1) ng.mL-1 and (3.9 +/- 1.4) ng.mL-1, T1/2 beta were (4.5 +/- 1.5) h and (4.6 +/- 1.1) h, respectively.",[Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579942/),h,0.22,16472,DB01001,Salbutamol
,12579942,Tmax,"The pharmacokinetics of salbutamol aersol was described well with a two-compartment model, and the parameters for salbutamol inhaled and orally administered were assessed as follows: Tmax were (0.22 +/- 0.07) h and (1.8 +/- 0.6) h, Cmax were (3.4 +/- 1.1) ng.mL-1 and (3.9 +/- 1.4) ng.mL-1, T1/2 beta were (4.5 +/- 1.5) h and (4.6 +/- 1.1) h, respectively.",[Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579942/),h,1.8,16473,DB01001,Salbutamol
,12579942,Cmax,"The pharmacokinetics of salbutamol aersol was described well with a two-compartment model, and the parameters for salbutamol inhaled and orally administered were assessed as follows: Tmax were (0.22 +/- 0.07) h and (1.8 +/- 0.6) h, Cmax were (3.4 +/- 1.1) ng.mL-1 and (3.9 +/- 1.4) ng.mL-1, T1/2 beta were (4.5 +/- 1.5) h and (4.6 +/- 1.1) h, respectively.",[Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579942/),[ng] / [ml],3.4,16474,DB01001,Salbutamol
,12579942,Cmax,"The pharmacokinetics of salbutamol aersol was described well with a two-compartment model, and the parameters for salbutamol inhaled and orally administered were assessed as follows: Tmax were (0.22 +/- 0.07) h and (1.8 +/- 0.6) h, Cmax were (3.4 +/- 1.1) ng.mL-1 and (3.9 +/- 1.4) ng.mL-1, T1/2 beta were (4.5 +/- 1.5) h and (4.6 +/- 1.1) h, respectively.",[Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579942/),[ng] / [ml],3.9,16475,DB01001,Salbutamol
,12579942,T1/2 beta,"The pharmacokinetics of salbutamol aersol was described well with a two-compartment model, and the parameters for salbutamol inhaled and orally administered were assessed as follows: Tmax were (0.22 +/- 0.07) h and (1.8 +/- 0.6) h, Cmax were (3.4 +/- 1.1) ng.mL-1 and (3.9 +/- 1.4) ng.mL-1, T1/2 beta were (4.5 +/- 1.5) h and (4.6 +/- 1.1) h, respectively.",[Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579942/),h,4.5,16476,DB01001,Salbutamol
,12579942,T1/2 beta,"The pharmacokinetics of salbutamol aersol was described well with a two-compartment model, and the parameters for salbutamol inhaled and orally administered were assessed as follows: Tmax were (0.22 +/- 0.07) h and (1.8 +/- 0.6) h, Cmax were (3.4 +/- 1.1) ng.mL-1 and (3.9 +/- 1.4) ng.mL-1, T1/2 beta were (4.5 +/- 1.5) h and (4.6 +/- 1.1) h, respectively.",[Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579942/),h,4.6,16477,DB01001,Salbutamol
,12579942,relative bioavailability,The relative bioavailability of salbutamol aerosol was 57.23% compared with its oral solution.,[Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579942/),%,57.23,16478,DB01001,Salbutamol
,30232958,Cmax,"Following single dosing, Cmax values were 8.07 ± 1.31 ng/mL and 25.7 ± 6.5 ng/mL for salbutamol and ambroxol, respectively.",Pharmacokinetics and safety of salbutamol/ambroxol fixed-dose combination granules in healthy Chinese subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30232958/),[ng] / [ml],8.07,17644,DB01001,Salbutamol
,30232958,Cmax,"Following single dosing, Cmax values were 8.07 ± 1.31 ng/mL and 25.7 ± 6.5 ng/mL for salbutamol and ambroxol, respectively.",Pharmacokinetics and safety of salbutamol/ambroxol fixed-dose combination granules in healthy Chinese subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30232958/),[ng] / [ml],25.7,17645,DB01001,Salbutamol
,30232958,T1/2,"The corresponding T1/2 values were 8.15 ± 3.13 hours and 9.31 ± 2.27 hours, respectively.",Pharmacokinetics and safety of salbutamol/ambroxol fixed-dose combination granules in healthy Chinese subjects . ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30232958/),h,8.15,17646,DB01001,Salbutamol
,30232958,T1/2,"The corresponding T1/2 values were 8.15 ± 3.13 hours and 9.31 ± 2.27 hours, respectively.",Pharmacokinetics and safety of salbutamol/ambroxol fixed-dose combination granules in healthy Chinese subjects . ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30232958/),h,9.31,17647,DB01001,Salbutamol
,29716857,flow rate,The mobile phase consisting of Potassium dihydrogen phosphate buffer pH (4.9)-Acetonitrile-Methanol (30:50:20 v/v) at flow rate of 1.0mL/min.,Development of a rapid resolution HPLC method for the quantitative determination of sitagliptin in Human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716857/),[ml] / [min],1.0,22126,DB01001,Salbutamol
,29716857,extraction recovery,"The extraction recovery was 97.6%, 92.2% and 91.96% at the concentrations of 6.25, 25 and 100μg/mL, respectively.",Development of a rapid resolution HPLC method for the quantitative determination of sitagliptin in Human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716857/),%,97.6,22127,DB01001,Salbutamol
,29716857,extraction recovery,"The extraction recovery was 97.6%, 92.2% and 91.96% at the concentrations of 6.25, 25 and 100μg/mL, respectively.",Development of a rapid resolution HPLC method for the quantitative determination of sitagliptin in Human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716857/),%,92.2,22128,DB01001,Salbutamol
,29716857,extraction recovery,"The extraction recovery was 97.6%, 92.2% and 91.96% at the concentrations of 6.25, 25 and 100μg/mL, respectively.",Development of a rapid resolution HPLC method for the quantitative determination of sitagliptin in Human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716857/),%,91.96,22129,DB01001,Salbutamol
,10383538,renal excretion,"Following INH dosing, the renal excretion was significantly higher (P<0.01) with 32.9 (14.5) microg, 61.2 (28.3) microg and 305.6 (82.3) microg excreted, respectively.","Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383538/),μg,32.9,22965,DB01001,Salbutamol
,10383538,renal excretion,"Following INH dosing, the renal excretion was significantly higher (P<0.01) with 32.9 (14.5) microg, 61.2 (28.3) microg and 305.6 (82.3) microg excreted, respectively.","Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383538/),μg,61.2,22966,DB01001,Salbutamol
,10383538,renal excretion,"Following INH dosing, the renal excretion was significantly higher (P<0.01) with 32.9 (14.5) microg, 61.2 (28.3) microg and 305.6 (82.3) microg excreted, respectively.","Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383538/),creted·e·μg,305.6,22967,DB01001,Salbutamol
,10383538,excreted,"The SCG excreted at 0.5, 1.0 and 24 h collection periods following INHC dosing were 26.3 (8.4) microg, 49.3 (18.1) microg and 184.9 (98.4) microg, respectively.","Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383538/),μg,26.3,22968,DB01001,Salbutamol
,10383538,excreted,"The SCG excreted at 0.5, 1.0 and 24 h collection periods following INHC dosing were 26.3 (8.4) microg, 49.3 (18.1) microg and 184.9 (98.4) microg, respectively.","Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383538/),μg,49.3,22969,DB01001,Salbutamol
,10383538,excreted,"The SCG excreted at 0.5, 1.0 and 24 h collection periods following INHC dosing were 26.3 (8.4) microg, 49.3 (18.1) microg and 184.9 (98.4) microg, respectively.","Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383538/),μg,184.9,22970,DB01001,Salbutamol
,3731682,peak expiratory flow rate (PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],336,26251,DB01001,Salbutamol
,3731682,peak expiratory flow rate (PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],349,26252,DB01001,Salbutamol
,3731682,PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],393,26253,DB01001,Salbutamol
,3731682,PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],367,26254,DB01001,Salbutamol
,3731682,steady-state serum,"Nifedipine did not significantly affect the steady-state serum theophylline trough levels (9.1 +/- 2.2 mg/ml for drug vs. 10.2 +/- 1.9 micrograms/ml for placebo) or the theophylline pharmacokinetic parameters, such as the elimination t1/2, peak serum concentration, time to peak, and AUC(0-24).",Effect of nifedipine and theophylline in asthma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[mg] / [ml],9.1,26255,DB01001,Salbutamol
,3731682,trough levels,"Nifedipine did not significantly affect the steady-state serum theophylline trough levels (9.1 +/- 2.2 mg/ml for drug vs. 10.2 +/- 1.9 micrograms/ml for placebo) or the theophylline pharmacokinetic parameters, such as the elimination t1/2, peak serum concentration, time to peak, and AUC(0-24).",Effect of nifedipine and theophylline in asthma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[mg] / [ml],9.1,26256,DB01001,Salbutamol
,3731682,trough levels,"Nifedipine did not significantly affect the steady-state serum theophylline trough levels (9.1 +/- 2.2 mg/ml for drug vs. 10.2 +/- 1.9 micrograms/ml for placebo) or the theophylline pharmacokinetic parameters, such as the elimination t1/2, peak serum concentration, time to peak, and AUC(0-24).",Effect of nifedipine and theophylline in asthma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[μg] / [ml],10.2,26257,DB01001,Salbutamol
,19443162,LOD,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],4.0,32282,DB01001,Salbutamol
,19443162,LOD,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],12.12,32283,DB01001,Salbutamol
,19443162,LOD,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],4.80,32284,DB01001,Salbutamol
,19443162,LOD,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],14.56,32285,DB01001,Salbutamol
,19443162,LOQ,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],12.12,32286,DB01001,Salbutamol
,19443162,LOQ,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],14.56,32287,DB01001,Salbutamol
,19443162,recoveries,The mean (RSD) SPE recoveries of salbutamol were 90.82% (2.32%) for USAL and 91.54% (2.96%) for USALMET.,New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),%,90.82,32288,DB01001,Salbutamol
,19443162,recoveries,The mean (RSD) SPE recoveries of salbutamol were 90.82% (2.32%) for USAL and 91.54% (2.96%) for USALMET.,New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),%,91.54,32289,DB01001,Salbutamol
,12895197,urinary,"The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively.",Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895197/),μg,2.61,37059,DB01001,Salbutamol
,12895197,urinary,"The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively.",Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895197/),μg,5.47,37060,DB01001,Salbutamol
,12895197,urinary,"The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively.",Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895197/),μg,8.68,37061,DB01001,Salbutamol
,12895197,urinary,"The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively.",Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895197/),μg,12.34,37062,DB01001,Salbutamol
,12895197,urinary,"The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively.",Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895197/),μg,15.99,37063,DB01001,Salbutamol
,12895197,salbutamol,"The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively.",Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895197/),μg,2.61,37064,DB01001,Salbutamol
,12895197,salbutamol,"The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively.",Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895197/),μg,5.47,37065,DB01001,Salbutamol
,12895197,salbutamol,"The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively.",Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895197/),μg,8.68,37066,DB01001,Salbutamol
,12895197,salbutamol,"The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively.",Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895197/),μg,12.34,37067,DB01001,Salbutamol
,12895197,salbutamol,"The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively.",Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895197/),μg,15.99,37068,DB01001,Salbutamol
,24825491,polydispersity index (PDI),The polydispersity index (PDI) was 0.12 ± 0.05 and the zeta potential was -33.2 ± 1.4 mV.,"Enhanced oral bioavailability of salmeterol by loaded PLGA microspheres: preparation, in vitro, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24825491/),,0.12,39019,DB01001,Salbutamol
,24825491,zeta potential,The polydispersity index (PDI) was 0.12 ± 0.05 and the zeta potential was -33.2 ± 1.4 mV.,"Enhanced oral bioavailability of salmeterol by loaded PLGA microspheres: preparation, in vitro, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24825491/),mv,-,39020,DB01001,Salbutamol
,24825491,zeta potential,The polydispersity index (PDI) was 0.12 ± 0.05 and the zeta potential was -33.2 ± 1.4 mV.,"Enhanced oral bioavailability of salmeterol by loaded PLGA microspheres: preparation, in vitro, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24825491/),mv,33.2,39021,DB01001,Salbutamol
,8970351,Area under the curve (AUC0-30),Area under the curve (AUC0-30) in the mechanically ventilated patients was 16.8 +/- 1.4 versus 23.4 +/- 1.9 ng/ml/puff x min in control subjects (p = 0.014).,Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered-dose inhaler administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8970351/),[ng] / [min·ml·puff],16.8,42269,DB01001,Salbutamol
,8970351,Area under the curve (AUC0-30),Area under the curve (AUC0-30) in the mechanically ventilated patients was 16.8 +/- 1.4 versus 23.4 +/- 1.9 ng/ml/puff x min in control subjects (p = 0.014).,Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered-dose inhaler administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8970351/),[ng] / [min·ml·puff],23.4,42270,DB01001,Salbutamol
,27129716,flow rate,Separation was achieved on Waters Acquity UPLC BEH C18 column using a gradient program at a flow rate of 0.2 mL/min.,Simultaneous determination of ambroxol and salbutamol in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129716/),[ml] / [min],0.2,43131,DB01001,Salbutamol
,27129716,total analytical run time,The total analytical run time was relatively short (3 min).,Simultaneous determination of ambroxol and salbutamol in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129716/),min,3,43132,DB01001,Salbutamol
,28374512,RL,The estimated RL value was 13% suggesting a high gut deposition of inhaled salmeterol.,Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28374512/),%,13,45602,DB01001,Salbutamol
,8866927,Cmax,"CFC-free produced significantly higher plasma salbutamol levels (ng ml-1; mean and 95% CI for difference) than either CFC or DPI: Cmax, CFC-free 4.18 vs CFC 3.29 (95% CI 0.10-1.68), vs DPI 3.42 (95% CI -0.03-1.56).","Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866927/),,4.18,46571,DB01001,Salbutamol
,8866927,Cmax,"CFC-free produced significantly higher plasma salbutamol levels (ng ml-1; mean and 95% CI for difference) than either CFC or DPI: Cmax, CFC-free 4.18 vs CFC 3.29 (95% CI 0.10-1.68), vs DPI 3.42 (95% CI -0.03-1.56).","Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866927/),,3.29,46572,DB01001,Salbutamol
,8866927,Cmax,"CFC-free produced significantly higher plasma salbutamol levels (ng ml-1; mean and 95% CI for difference) than either CFC or DPI: Cmax, CFC-free 4.18 vs CFC 3.29 (95% CI 0.10-1.68), vs DPI 3.42 (95% CI -0.03-1.56).","Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866927/),,3.42,46573,DB01001,Salbutamol
>,25168793,m/z,"Triple quadrupole mass detection with multiple reaction monitoring (MRM) mode was used to monitor the ion transitions, m/z of 369>285 for curcumin, and m/z of 240>148 for salbutamol.",A validated LC-MS/MS method for quantitative analysis of curcumin in mouse plasma and brain tissue and its application in pharmacokinetic and brain distribution studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25168793/),,369,50870,DB01001,Salbutamol
>,25168793,m/z,"Triple quadrupole mass detection with multiple reaction monitoring (MRM) mode was used to monitor the ion transitions, m/z of 369>285 for curcumin, and m/z of 240>148 for salbutamol.",A validated LC-MS/MS method for quantitative analysis of curcumin in mouse plasma and brain tissue and its application in pharmacokinetic and brain distribution studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25168793/),,285,50871,DB01001,Salbutamol
>,25168793,m/z,"Triple quadrupole mass detection with multiple reaction monitoring (MRM) mode was used to monitor the ion transitions, m/z of 369>285 for curcumin, and m/z of 240>148 for salbutamol.",A validated LC-MS/MS method for quantitative analysis of curcumin in mouse plasma and brain tissue and its application in pharmacokinetic and brain distribution studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25168793/),,240,50872,DB01001,Salbutamol
>,25168793,m/z,"Triple quadrupole mass detection with multiple reaction monitoring (MRM) mode was used to monitor the ion transitions, m/z of 369>285 for curcumin, and m/z of 240>148 for salbutamol.",A validated LC-MS/MS method for quantitative analysis of curcumin in mouse plasma and brain tissue and its application in pharmacokinetic and brain distribution studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25168793/),,148,50873,DB01001,Salbutamol
,32165316,USAL0.5,"The mean (SD) USAL0.5 of VC and AS was 5.36 (4.48) and 12.80 (10.83) µg, respectively.",Comparative pharmacokinetics of salbutamol inhaled from a pressurized metered dose inhaler either alone or connected to a newly enhanced spacer design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32165316/),μg,5.36,52662,DB01001,Salbutamol
,32165316,USAL0.5,"The mean (SD) USAL0.5 of VC and AS was 5.36 (4.48) and 12.80 (10.83) µg, respectively.",Comparative pharmacokinetics of salbutamol inhaled from a pressurized metered dose inhaler either alone or connected to a newly enhanced spacer design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32165316/),μg,12.80,52663,DB01001,Salbutamol
,32165316,OD,"The mean (SD) OD was 11.35 (3.37) and 0.48 (0.30) µg, respectively.",Comparative pharmacokinetics of salbutamol inhaled from a pressurized metered dose inhaler either alone or connected to a newly enhanced spacer design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32165316/),μg,11.35,52664,DB01001,Salbutamol
,32165316,OD,"The mean (SD) OD was 11.35 (3.37) and 0.48 (0.30) µg, respectively.",Comparative pharmacokinetics of salbutamol inhaled from a pressurized metered dose inhaler either alone or connected to a newly enhanced spacer design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32165316/),μg,0.48,52665,DB01001,Salbutamol
,10856145,peak expiratory flow,"Treatment with FP was more effective than treatment with zafirlukast in increasing morning FEV(1) (by 0.42 L vs 0.20 L over baseline, P <.001), morning peak expiratory flow (by 49.94 L/min vs 11.68 L/min over baseline, P <. 001), and evening PEF (by 38.91 L/min vs 10.50 L/min over baseline, P <.001).",Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856145/),[l] / [min],49.94,52904,DB01001,Salbutamol
,10856145,peak expiratory flow,"Treatment with FP was more effective than treatment with zafirlukast in increasing morning FEV(1) (by 0.42 L vs 0.20 L over baseline, P <.001), morning peak expiratory flow (by 49.94 L/min vs 11.68 L/min over baseline, P <. 001), and evening PEF (by 38.91 L/min vs 10.50 L/min over baseline, P <.001).",Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856145/),[l] / [min],11.68,52905,DB01001,Salbutamol
,1432626,terminal half-life,"The pharmacokinetic parameters determined after intravenous and transdermal administration were as follows: terminal half-life, 2.26 +/- 0.45 h; apparent volume of distribution, 1935 +/- 37.2 mL.kg-1; and total body clearance, 612.0 +/- 118 mL.h-1.kg-1.",Transdermal drug delivery systems of albuterol: in vitro and in vivo studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432626/),h,2.26,53840,DB01001,Salbutamol
,1432626,apparent volume of distribution,"The pharmacokinetic parameters determined after intravenous and transdermal administration were as follows: terminal half-life, 2.26 +/- 0.45 h; apparent volume of distribution, 1935 +/- 37.2 mL.kg-1; and total body clearance, 612.0 +/- 118 mL.h-1.kg-1.",Transdermal drug delivery systems of albuterol: in vitro and in vivo studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432626/),[ml] / [kg],1935,53841,DB01001,Salbutamol
,1432626,total body clearance,"The pharmacokinetic parameters determined after intravenous and transdermal administration were as follows: terminal half-life, 2.26 +/- 0.45 h; apparent volume of distribution, 1935 +/- 37.2 mL.kg-1; and total body clearance, 612.0 +/- 118 mL.h-1.kg-1.",Transdermal drug delivery systems of albuterol: in vitro and in vivo studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432626/),[ml] / [h·kg],612.0,53842,DB01001,Salbutamol
,1432626,concentrations,"The average concentrations in serum after application of single- and double-layer pads were 44.60 +/- 16.40 and 62.50 +/- 8.00 ng/mL, respectively.",Transdermal drug delivery systems of albuterol: in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432626/),[ng] / [ml],44.60,53843,DB01001,Salbutamol
,1432626,concentrations,"The average concentrations in serum after application of single- and double-layer pads were 44.60 +/- 16.40 and 62.50 +/- 8.00 ng/mL, respectively.",Transdermal drug delivery systems of albuterol: in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432626/),[ng] / [ml],62.50,53844,DB01001,Salbutamol
,16303295,minimum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),[mM] / [l],3.4,54760,DB01001,Salbutamol
,16303295,minimum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),[mM] / [l],3.3,54761,DB01001,Salbutamol
,16303295,maximum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),,9.0,54762,DB01001,Salbutamol
,16303295,maximum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),,8.7,54763,DB01001,Salbutamol
,16303295,maximum forced expiratory volume,"Both drugs improved lung function (mean maximum forced expiratory volume in 1s [FEV(1)] 2.6 l with both treatments; P=0.624), with the improvement being significantly greater with formoterol than with salbutamol on all 3 days of treatment (mean area under the curve [AUC](0-24 h) of FEV(1) formoterol vs. salbutamol on days 1-3, all P<0.05).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),l,2.6,54764,DB01001,Salbutamol
,2913132,areas under the curve,"The areas under the curve were 100 and 105 hr.ng/ml when the drug was administered with and without food, respectively.",Influence of food on the absorption of albuterol Repetabs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913132/),[h·ng] / [ml],100,55928,DB01001,Salbutamol
,2913132,areas under the curve,"The areas under the curve were 100 and 105 hr.ng/ml when the drug was administered with and without food, respectively.",Influence of food on the absorption of albuterol Repetabs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913132/),[h·ng] / [ml],105,55929,DB01001,Salbutamol
,2913132,peak plasma concentration,"The corresponding peak plasma concentration values were 9.4 and 10.4 ng/ml, respectively.",Influence of food on the absorption of albuterol Repetabs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913132/),[ng] / [ml],9.4,55930,DB01001,Salbutamol
,2913132,peak plasma concentration,"The corresponding peak plasma concentration values were 9.4 and 10.4 ng/ml, respectively.",Influence of food on the absorption of albuterol Repetabs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913132/),[ng] / [ml],10.4,55931,DB01001,Salbutamol
,31432470,clearance,"A two-compartment model with separate clearance for R- and S-salbutamol (16.3 L/h and 8.8 L/h, respectively) best described the data.",Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31432470/),[l] / [h],16.3,57012,DB01001,Salbutamol
,31432470,clearance,"A two-compartment model with separate clearance for R- and S-salbutamol (16.3 L/h and 8.8 L/h, respectively) best described the data.",Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31432470/),[l] / [h],8.8,57013,DB01001,Salbutamol
,20055182,zero-,"The zero-moment rations of SS/A-31 MDI formulation to contrast sample and CFC SS MDI was 143.26% and 147.01%, respectively.",[Isobutane driven salbutamol sulfate metered dose inhaler: formulation selection and respiratory tract absorption in guinea pigs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20055182/),,143,58878,DB01001,Salbutamol
,20055182,zero-,"The zero-moment rations of SS/A-31 MDI formulation to contrast sample and CFC SS MDI was 143.26% and 147.01%, respectively.",[Isobutane driven salbutamol sulfate metered dose inhaler: formulation selection and respiratory tract absorption in guinea pigs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20055182/),,147,58879,DB01001,Salbutamol
,29493402,time to maximum concentration (tmax),Median salmeterol time to maximum concentration (tmax) was 4.0 minutes.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),min,4.0,60836,DB01001,Salbutamol
,29493402,tmax,Median fluticasone propionate tmax was from 1.5 to 2.0 hours.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),h,1.5 to 2.0,60837,DB01001,Salbutamol
,29493402,Terminal elimination half-life,Terminal elimination half-life was 11 hours for salmeterol and 9-10 hours for fluticasone propionate.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),h,11,60838,DB01001,Salbutamol
,29493402,Terminal elimination half-life,Terminal elimination half-life was 11 hours for salmeterol and 9-10 hours for fluticasone propionate.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),h,9-10,60839,DB01001,Salbutamol
,12072587,rate-pressure product,"Salmeterol increased mean rate-pressure product by 5% (salmeterol 8878 +/- 1560 vs. placebo 8414 +/- 1440 bpm x mm Hg, p = 0.04), although no increase in plasma norepinephrine, epinephrine, plasma renin activity or ventricular ectopy was detected.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),bpm·hg·mm,8878,61872,DB01001,Salbutamol
,12072587,rate-pressure product,"Salmeterol increased mean rate-pressure product by 5% (salmeterol 8878 +/- 1560 vs. placebo 8414 +/- 1440 bpm x mm Hg, p = 0.04), although no increase in plasma norepinephrine, epinephrine, plasma renin activity or ventricular ectopy was detected.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),bpm·hg·mm,8414,61873,DB01001,Salbutamol
,12072587,Tmax,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),min,5,61874,DB01001,Salbutamol
,12072587,Cmax,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),[pg] / [ml],715,61875,DB01001,Salbutamol
,12072587,half-life,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),h,11.4,61876,DB01001,Salbutamol
,18192544,area under the curve(0-t'),"AIR insulin exposure was reduced 34 and 41% (both P < 0.01) in asthmatic subjects (area under the curve(0-t'), 24.0 and 21.1 nmol x min x l(-1) in mild and moderate asthma subjects, respectively) compared with healthy subjects (35.2 nmol x min x l(-1)), respectively.","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),[min·nM] / [l],24.0,62244,DB01001,Salbutamol
,18192544,area under the curve(0-t'),"AIR insulin exposure was reduced 34 and 41% (both P < 0.01) in asthmatic subjects (area under the curve(0-t'), 24.0 and 21.1 nmol x min x l(-1) in mild and moderate asthma subjects, respectively) compared with healthy subjects (35.2 nmol x min x l(-1)), respectively.","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),[min·nM] / [l],21.1,62245,DB01001,Salbutamol
,18192544,area under the curve(0-t'),"AIR insulin exposure was reduced 34 and 41% (both P < 0.01) in asthmatic subjects (area under the curve(0-t'), 24.0 and 21.1 nmol x min x l(-1) in mild and moderate asthma subjects, respectively) compared with healthy subjects (35.2 nmol x min x l(-1)), respectively.","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),[min·nM] / [l],35.2,62246,DB01001,Salbutamol
,18192544,G(tot),"Glucodynamic (G) effects were similar in healthy and mildly asthmatic subjects (G(tot) = 38.7 and 23.4 g, respectively; P = 0.16) and were reduced in moderately asthmatic subjects (G(tot) = 10.7 g).","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),g,38.7,62247,DB01001,Salbutamol
,18192544,G(tot),"Glucodynamic (G) effects were similar in healthy and mildly asthmatic subjects (G(tot) = 38.7 and 23.4 g, respectively; P = 0.16) and were reduced in moderately asthmatic subjects (G(tot) = 10.7 g).","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),g,23.4,62248,DB01001,Salbutamol
,18192544,G(tot),"Glucodynamic (G) effects were similar in healthy and mildly asthmatic subjects (G(tot) = 38.7 and 23.4 g, respectively; P = 0.16) and were reduced in moderately asthmatic subjects (G(tot) = 10.7 g).","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),g,10.7,62249,DB01001,Salbutamol
,11601748,forced expiratory volume in 1 sec (FEV1),"A total of 24 patients with COPD were randomized [mean age 61.6 +/- 7.8 years, mean forced expiratory volume in 1 sec (FEV1) 1.38 +/- 0.32 l and 45.8 +/- 9.6% of predicted].",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),l,1.38,62345,DB01001,Salbutamol
,11601748,forced expiratory volume in 1 sec (FEV1),"A total of 24 patients with COPD were randomized [mean age 61.6 +/- 7.8 years, mean forced expiratory volume in 1 sec (FEV1) 1.38 +/- 0.32 l and 45.8 +/- 9.6% of predicted].",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),%,45.8,62346,DB01001,Salbutamol
,11601748,area under the curve (AUC),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],5.89,62347,DB01001,Salbutamol
,11601748,area under the curve (AUC),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],6.06,62348,DB01001,Salbutamol
,11601748,AUC(0-30 min),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],5.89,62349,DB01001,Salbutamol
,11601748,AUC(0-30 min),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],6.06,62350,DB01001,Salbutamol
,2991865,half-life,The long half-life previously reported in the literature (7 hours) is mainly the half-life of inactive fenoterol metabolites.,"Fenoterol: a beta2-adrenergic agonist for use in asthma. Pharmacology, pharmacokinetics, clinical efficacy and adverse effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991865/),h,7,66681,DB01001,Salbutamol
,15541911,input rate,"Transdermal drug delivery formulation containing 5 mg/patch of salbutamol sulfate (SS), providing an input rate of 100 microg/h of SS was formulated and subjected for pharmacokinetic and pharmacodynamic evaluation in moderately asthmatic patients (n=6).",Clinical pharmacokinetic and pharmacodynamic evaluation of transdermal drug delivery systems of salbutamol sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541911/),[μg] / [h],100,66699,DB01001,Salbutamol
,15541911,steady-state serum concentration,A steady-state serum concentration of 2.87+/-0.1 ng/ml (per milligram dose) was attained after an initial lag period of 4.67+/-1.03 h.,Clinical pharmacokinetic and pharmacodynamic evaluation of transdermal drug delivery systems of salbutamol sulfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541911/),[ng] / [ml],2.87,66700,DB01001,Salbutamol
,15541911,initial lag period,A steady-state serum concentration of 2.87+/-0.1 ng/ml (per milligram dose) was attained after an initial lag period of 4.67+/-1.03 h.,Clinical pharmacokinetic and pharmacodynamic evaluation of transdermal drug delivery systems of salbutamol sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541911/),h,4.67,66701,DB01001,Salbutamol
,15541911,elimination half-life,"The elimination half-life, clearance rate and elimination rate constant was 3.35+/-1.07 h, 256.12+/-3.55 ml/min and 0.24+/-0.09 h(-1), respectively.",Clinical pharmacokinetic and pharmacodynamic evaluation of transdermal drug delivery systems of salbutamol sulfate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541911/),h,3.35,66702,DB01001,Salbutamol
,15541911,clearance rate,"The elimination half-life, clearance rate and elimination rate constant was 3.35+/-1.07 h, 256.12+/-3.55 ml/min and 0.24+/-0.09 h(-1), respectively.",Clinical pharmacokinetic and pharmacodynamic evaluation of transdermal drug delivery systems of salbutamol sulfate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541911/),[ml] / [min],256.12,66703,DB01001,Salbutamol
,15541911,elimination rate constant,"The elimination half-life, clearance rate and elimination rate constant was 3.35+/-1.07 h, 256.12+/-3.55 ml/min and 0.24+/-0.09 h(-1), respectively.",Clinical pharmacokinetic and pharmacodynamic evaluation of transdermal drug delivery systems of salbutamol sulfate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541911/),1/[h],0.24,66704,DB01001,Salbutamol
,15541911,forced expiratory volume in one minute (FEV1),The mean forced expiratory volume in one minute (FEV1) of the patients was 2.2+/-0.14l during steady state.,Clinical pharmacokinetic and pharmacodynamic evaluation of transdermal drug delivery systems of salbutamol sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541911/),l,2.2,66705,DB01001,Salbutamol
,19473604,AUC(0-yen),"The mean AUC(0-yen) values were 91.26 and 96.45 h.ng/ml for reference and test product, respectively.",Comparative bioavailability study of two salbutamol tablets in healthy adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473604/),[h·ng] / [ml],91.26,66838,DB01001,Salbutamol
,19473604,AUC(0-yen),"The mean AUC(0-yen) values were 91.26 and 96.45 h.ng/ml for reference and test product, respectively.",Comparative bioavailability study of two salbutamol tablets in healthy adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473604/),[h·ng] / [ml],96.45,66839,DB01001,Salbutamol
,19473604,C(max),"The mean C(max) values were 12.26 and 12.38 ng/ml and the mean t(max) values were 2.80 and 2.33 hours for reference and test product, respectively.",Comparative bioavailability study of two salbutamol tablets in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473604/),[ng] / [ml],12.26,66840,DB01001,Salbutamol
,19473604,C(max),"The mean C(max) values were 12.26 and 12.38 ng/ml and the mean t(max) values were 2.80 and 2.33 hours for reference and test product, respectively.",Comparative bioavailability study of two salbutamol tablets in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473604/),[ng] / [ml],12.38,66841,DB01001,Salbutamol
,19473604,t(max),"The mean C(max) values were 12.26 and 12.38 ng/ml and the mean t(max) values were 2.80 and 2.33 hours for reference and test product, respectively.",Comparative bioavailability study of two salbutamol tablets in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473604/),h,2.80,66842,DB01001,Salbutamol
,19473604,t(max),"The mean C(max) values were 12.26 and 12.38 ng/ml and the mean t(max) values were 2.80 and 2.33 hours for reference and test product, respectively.",Comparative bioavailability study of two salbutamol tablets in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473604/),h,2.33,66843,DB01001,Salbutamol
,1287197,total plasma clearance,"Following iv salbutamol (60 micrograms/kg), total plasma clearance was 82 +/- 5 ml/min per kg, apparent volume of distribution was 5.0 +/- 0.5 l/kg, and terminal half-life was 41 +/- 2 min.",Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287197/),[ml] / [kg·min],82,71422,DB01001,Salbutamol
,1287197,apparent volume of distribution,"Following iv salbutamol (60 micrograms/kg), total plasma clearance was 82 +/- 5 ml/min per kg, apparent volume of distribution was 5.0 +/- 0.5 l/kg, and terminal half-life was 41 +/- 2 min.",Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287197/),[l] / [kg],5.0,71423,DB01001,Salbutamol
,1287197,terminal half-life,"Following iv salbutamol (60 micrograms/kg), total plasma clearance was 82 +/- 5 ml/min per kg, apparent volume of distribution was 5.0 +/- 0.5 l/kg, and terminal half-life was 41 +/- 2 min.",Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287197/),min,41,71424,DB01001,Salbutamol
,1287197,bioavailability,"The bioavailability of po and it salbutamol was approximately 1 and 20%, respectively.",Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287197/),%,1,71425,DB01001,Salbutamol
,1287197,bioavailability,"The bioavailability of po and it salbutamol was approximately 1 and 20%, respectively.",Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287197/),%,20,71426,DB01001,Salbutamol
,1287197,maximal,"For the first group, the maximal decrease in plasma potassium elicited by salbutamol was 0.80 +/- 0.19, 0.48 +/- 0.22, and 0.78 +/- 0.46 mmol/l, and for the second group, maximal decrement was 1.31 +/- 0.37, 0.70 +/- 0.24, and 0.84 +/- 0.17 mmol/l for the iv, po, and it routes, respectively.",Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287197/),[mM] / [l],0.80,71427,DB01001,Salbutamol
,1287197,maximal,"For the first group, the maximal decrease in plasma potassium elicited by salbutamol was 0.80 +/- 0.19, 0.48 +/- 0.22, and 0.78 +/- 0.46 mmol/l, and for the second group, maximal decrement was 1.31 +/- 0.37, 0.70 +/- 0.24, and 0.84 +/- 0.17 mmol/l for the iv, po, and it routes, respectively.",Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287197/),[mM] / [l],0.48,71428,DB01001,Salbutamol
,1287197,maximal,"For the first group, the maximal decrease in plasma potassium elicited by salbutamol was 0.80 +/- 0.19, 0.48 +/- 0.22, and 0.78 +/- 0.46 mmol/l, and for the second group, maximal decrement was 1.31 +/- 0.37, 0.70 +/- 0.24, and 0.84 +/- 0.17 mmol/l for the iv, po, and it routes, respectively.",Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287197/),[mM] / [l],0.78,71429,DB01001,Salbutamol
,1287197,maximal decrement,"For the first group, the maximal decrease in plasma potassium elicited by salbutamol was 0.80 +/- 0.19, 0.48 +/- 0.22, and 0.78 +/- 0.46 mmol/l, and for the second group, maximal decrement was 1.31 +/- 0.37, 0.70 +/- 0.24, and 0.84 +/- 0.17 mmol/l for the iv, po, and it routes, respectively.",Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287197/),[mM] / [l],1.31,71430,DB01001,Salbutamol
,1287197,maximal decrement,"For the first group, the maximal decrease in plasma potassium elicited by salbutamol was 0.80 +/- 0.19, 0.48 +/- 0.22, and 0.78 +/- 0.46 mmol/l, and for the second group, maximal decrement was 1.31 +/- 0.37, 0.70 +/- 0.24, and 0.84 +/- 0.17 mmol/l for the iv, po, and it routes, respectively.",Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287197/),[mM] / [l],0.70,71431,DB01001,Salbutamol
,1287197,maximal decrement,"For the first group, the maximal decrease in plasma potassium elicited by salbutamol was 0.80 +/- 0.19, 0.48 +/- 0.22, and 0.78 +/- 0.46 mmol/l, and for the second group, maximal decrement was 1.31 +/- 0.37, 0.70 +/- 0.24, and 0.84 +/- 0.17 mmol/l for the iv, po, and it routes, respectively.",Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287197/),[mM] / [l],0.84,71432,DB01001,Salbutamol
,9248783,Oral bioavailability,"Oral bioavailability was 80% and there were neither significant differences (P > 0.05) in terms of the calculation method used (relation of the areas under the plasma level curve Loo-Riegelman, deconvolution) nor in terms of the dosage form (Ventolin Volmax, SG7 and SG14).",Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248783/),%,80,74492,DB01001,Salbutamol
,9248783,elimination half-life,The elimination half-life value of salbutamol was 1.2 h when administered intravenously; this parameter had a value of 3.0 h for the immediate-release formulation and ranged between 5.4 and 7.2 h in the sustained-release formulations when administered orally.,Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248783/),h,1.2,74493,DB01001,Salbutamol
,9248783,elimination half-life,The elimination half-life value of salbutamol was 1.2 h when administered intravenously; this parameter had a value of 3.0 h for the immediate-release formulation and ranged between 5.4 and 7.2 h in the sustained-release formulations when administered orally.,Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248783/),h,3.0,74494,DB01001,Salbutamol
,9248783,elimination half-life,The elimination half-life value of salbutamol was 1.2 h when administered intravenously; this parameter had a value of 3.0 h for the immediate-release formulation and ranged between 5.4 and 7.2 h in the sustained-release formulations when administered orally.,Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248783/),h,5.4 and 7.2,74495,DB01001,Salbutamol
,22388343,concentrations,Median concentrations after inhaled salbutamol and oral salbutamol were 401.6 and 2108.1 ng/mL in healthy subjects and 334.9 and 2975.2 ng/mL in elite athletes with asthma.,The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22388343/),[ng] / [ml],401.6,75980,DB01001,Salbutamol
,22388343,concentrations,Median concentrations after inhaled salbutamol and oral salbutamol were 401.6 and 2108.1 ng/mL in healthy subjects and 334.9 and 2975.2 ng/mL in elite athletes with asthma.,The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22388343/),[ng] / [ml],2108.1,75981,DB01001,Salbutamol
,22388343,concentrations,Median concentrations after inhaled salbutamol and oral salbutamol were 401.6 and 2108.1 ng/mL in healthy subjects and 334.9 and 2975.2 ng/mL in elite athletes with asthma.,The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22388343/),[ng] / [ml],334.9,75982,DB01001,Salbutamol
,22388343,concentrations,Median concentrations after inhaled salbutamol and oral salbutamol were 401.6 and 2108.1 ng/mL in healthy subjects and 334.9 and 2975.2 ng/mL in elite athletes with asthma.,The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22388343/),[ng] / [ml],2975.2,75983,DB01001,Salbutamol
,26850676,AUC0-0.33 h,"The mean (SD) pharmacokinetic parameters of the reference drug were AUC0-0.33 h, 227.2 (89.9) pg·h/ml; AUC0-24 h, 2551.9 (1008.0) pg·h/ml; Cmax, 801.3 (307.3) pg/ml and t1/2, 5.14(1.36) h.",Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26850676/),[h·pg] / [ml],227.2,78428,DB01001,Salbutamol
,26850676,AUC0-24 h,"The mean (SD) pharmacokinetic parameters of the reference drug were AUC0-0.33 h, 227.2 (89.9) pg·h/ml; AUC0-24 h, 2551.9 (1008.0) pg·h/ml; Cmax, 801.3 (307.3) pg/ml and t1/2, 5.14(1.36) h.",Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26850676/),[h·pg] / [ml],2551.9,78429,DB01001,Salbutamol
,26850676,Cmax,"The mean (SD) pharmacokinetic parameters of the reference drug were AUC0-0.33 h, 227.2 (89.9) pg·h/ml; AUC0-24 h, 2551.9 (1008.0) pg·h/ml; Cmax, 801.3 (307.3) pg/ml and t1/2, 5.14(1.36) h.",Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26850676/),[pg] / [ml],801.3,78430,DB01001,Salbutamol
,26850676,t1/2,"The mean (SD) pharmacokinetic parameters of the reference drug were AUC0-0.33 h, 227.2 (89.9) pg·h/ml; AUC0-24 h, 2551.9 (1008.0) pg·h/ml; Cmax, 801.3 (307.3) pg/ml and t1/2, 5.14(1.36) h.",Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26850676/),h,5.14,78431,DB01001,Salbutamol
,26850676,AUC0-0.33 h,"Those of the test drug were AUC0-0.33 h, 244.0 (104.4) pg·h/ml; AUC0-24 h, 2664.4 (1081.8) pg·h/ml; Cmax, 873.7 (374.4) pg/ml, t1/2, 5.29 (1.23) h.",Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26850676/),[h·pg] / [ml],244.0,78432,DB01001,Salbutamol
,26850676,AUC0-24 h,"Those of the test drug were AUC0-0.33 h, 244.0 (104.4) pg·h/ml; AUC0-24 h, 2664.4 (1081.8) pg·h/ml; Cmax, 873.7 (374.4) pg/ml, t1/2, 5.29 (1.23) h.",Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26850676/),[h·pg] / [ml],2664.4,78433,DB01001,Salbutamol
,26850676,Cmax,"Those of the test drug were AUC0-0.33 h, 244.0 (104.4) pg·h/ml; AUC0-24 h, 2664.4 (1081.8) pg·h/ml; Cmax, 873.7 (374.4) pg/ml, t1/2, 5.29 (1.23) h.",Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26850676/),[pg] / [ml],873.7,78434,DB01001,Salbutamol
,26850676,t1/2,"Those of the test drug were AUC0-0.33 h, 244.0 (104.4) pg·h/ml; AUC0-24 h, 2664.4 (1081.8) pg·h/ml; Cmax, 873.7 (374.4) pg/ml, t1/2, 5.29 (1.23) h.",Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26850676/),h,5.29,78435,DB01001,Salbutamol
,26850676,Tmax,The median value for Tmax was 0.25 h for both formulations.,Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26850676/),h,0.25,78436,DB01001,Salbutamol
,9297839,analysis time,The analysis time is 8 min per sample.,Rapid pharmacokinetic screening of salbutamol in plasma samples by column-switching high-performance liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9297839/),[min] / [sample],8,79518,DB01001,Salbutamol
,34239296,%EE,The results showed that the prepared microspheres have a high %EE (97.11±0.78%) for F13.,"Superhydrophobic Surface for Enhancing the Bioavailability of Salbutamol Sulfate from Cross-Linked Microspheres: Formulation, Characterization, and in vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34239296/),%,97.11,79876,DB01001,Salbutamol
,34239296,swelling ratio,"The swelling ratio was 4.2 at the end of the 8 hours for the optimized formula, and the in vitro release rate was controlled for 12 hours.","Superhydrophobic Surface for Enhancing the Bioavailability of Salbutamol Sulfate from Cross-Linked Microspheres: Formulation, Characterization, and in vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34239296/),,4.2,79877,DB01001,Salbutamol
,30087193,bioavailability,"This trend did not extend to the 24-h levels, in which bioavailability with the large spacer plus pMDI (49.9%) was lower than with the T-piece (52.8%) and with the large spacer (54.3%).",Performance of Large Spacer Versus Nebulizer T-Piece in Single-Limb Noninvasive Ventilation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087193/),%,49.9,86123,DB01001,Salbutamol
,30087193,bioavailability,"This trend did not extend to the 24-h levels, in which bioavailability with the large spacer plus pMDI (49.9%) was lower than with the T-piece (52.8%) and with the large spacer (54.3%).",Performance of Large Spacer Versus Nebulizer T-Piece in Single-Limb Noninvasive Ventilation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087193/),%,52.8,86124,DB01001,Salbutamol
,30087193,bioavailability,"This trend did not extend to the 24-h levels, in which bioavailability with the large spacer plus pMDI (49.9%) was lower than with the T-piece (52.8%) and with the large spacer (54.3%).",Performance of Large Spacer Versus Nebulizer T-Piece in Single-Limb Noninvasive Ventilation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087193/),%,54.3,86125,DB01001,Salbutamol
,3228576,steady state Tmax,"Mean steady state Tmax values were 2.6 and 6.0 h for the TR and CR formulations, respectively.",Relative bioavailability of a controlled-release albuterol formulation for twice-daily use. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3228576/),h,2.6,90171,DB01001,Salbutamol
,3228576,steady state Tmax,"Mean steady state Tmax values were 2.6 and 6.0 h for the TR and CR formulations, respectively.",Relative bioavailability of a controlled-release albuterol formulation for twice-daily use. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3228576/),h,6.0,90172,DB01001,Salbutamol
,17723076,PC(20),"However, S-albuterol reduced the provocative concentration of methacholine to induce a 20% decrease in FEV(1) (PC(20) 0.52 +/- 2.06 vs 0.39 +/- 1.58 mg/ml, placebo vs S-albuterol, p=0.044) but did not affect FeNO.",Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723076/),[mg] / [ml],0.52,90637,DB01001,Salbutamol
,17723076,PC(20),"However, S-albuterol reduced the provocative concentration of methacholine to induce a 20% decrease in FEV(1) (PC(20) 0.52 +/- 2.06 vs 0.39 +/- 1.58 mg/ml, placebo vs S-albuterol, p=0.044) but did not affect FeNO.",Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723076/),[mg] / [ml],0.39,90638,DB01001,Salbutamol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],4.0,94365,DB01001,Salbutamol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],2.1,94366,DB01001,Salbutamol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],2.2,94367,DB01001,Salbutamol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],11.6,94368,DB01001,Salbutamol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],5.7,94369,DB01001,Salbutamol
,33210444,maximum urine concentrations,"Mean ± SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0 ± 1.6, 2.1 ± 1.5, and 2.2 ± 1.1 ng × ml-1 for 400 μg, 200 μg, and seven consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6 ± 6.1, 5.7 ± 4.6, and 6.5 ± 2.6 ng × ml-1 .",Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210444/),[ng] / [ml],6.5,94370,DB01001,Salbutamol
,10516540,reversibility,"In a double-blind, randomized, crossover and placebo-controlled study design, the respiratory functions of 22 patients (mean age 57.3+/-5.4 years) having mild to severe COPD (5 mild, 8 moderate and 9 severe) and partially reversible airway obstruction [mean baseline reversibility of forced expiratory volume in 1 s (FEV(1)) 19.3+/-3.1%] were evaluated after inhalation of 12 microg formoterol and 50 microg salmeterol.","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),%,19.3,95418,DB01001,Salbutamol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.39,95419,DB01001,Salbutamol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.40,95420,DB01001,Salbutamol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.02,95421,DB01001,Salbutamol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.12,95422,DB01001,Salbutamol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,3.5,95423,DB01001,Salbutamol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,3.2,95424,DB01001,Salbutamol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,1.2,95425,DB01001,Salbutamol
,8091320,aerosol rate of output,"The in vitro comparison showed a greater respirable fraction with a higher percentage volume of particles < 5 microns in diameter using Ventstream than Hudson nebulisers (mean (95% CI) for difference): 25.4% (95% CI 22.4% to 28.3%), and a higher aerosol rate of output: 0.08 g/min (95% CI 0.05 to 0.11 g/min).","Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (""Ventstream""). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8091320/),[g] / [min],0.08,97074,DB01001,Salbutamol
,8091320,AUC0-240,At the 5.0 mg dose the Ventstream produced a twofold greater concentration of plasma salbutamol than the Hudson nebuliser (AUC0-240): 392.1 ng/ml.min (95% CI 240.6 to 543.6 ng/ml.min).,"Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (""Ventstream""). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8091320/),[ng] / [min·ml],392.1,97075,DB01001,Salbutamol
,8091320,AUC0-240,There was a higher AUC0-240 for PEFR with the Ventstream than with the Hudson nebuliser: 74.161 x 10(2) (95% CI 39.50 to 108.821 x 10(2).,"Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (""Ventstream""). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8091320/),,74.161 x 10(2),97076,DB01001,Salbutamol
,30431426,AUC0-t,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],"1,622.64",98462,DB01001,Salbutamol
,30431426,AUC0-t,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],"1,487.52",98463,DB01001,Salbutamol
,30431426,Cmax,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],151.36,98464,DB01001,Salbutamol
,30431426,Cmax,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],137.57,98465,DB01001,Salbutamol
,30431426,AUC0-t,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],408.42,98466,DB01001,Salbutamol
,30431426,AUC0-t,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],401.79,98467,DB01001,Salbutamol
,30431426,Cmax,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],269.48,98468,DB01001,Salbutamol
,30431426,Cmax,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],265.66,98469,DB01001,Salbutamol
,3653233,terminal half-life,"Pharmacokinetic parameters from intravenous data were similar to previously reported values obtained with oral administration, with a mean terminal half-life of 3.8 h and a mean clearance of 439 ml X min-1 X 1.73 m-2.",Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653233/),h,3.8,102994,DB01001,Salbutamol
,3653233,clearance,"Pharmacokinetic parameters from intravenous data were similar to previously reported values obtained with oral administration, with a mean terminal half-life of 3.8 h and a mean clearance of 439 ml X min-1 X 1.73 m-2.",Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653233/),[1.73·ml] / [(m)^2·min],439,102995,DB01001,Salbutamol
,3653233,Peak plasma concentrations,Peak plasma concentrations of 10-20 ng X ml-1 were obtained 1-3 h following oral administration.,Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653233/),[ng] / [ml],10-20,102996,DB01001,Salbutamol
,3653233,absolute bioavailability,The absolute bioavailability of each of the oral preparations was 44%.,Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653233/),%,44,102997,DB01001,Salbutamol
,27216137,AUC0-12,"FEV1 AUC0-12 was significantly higher with all FS MDPI doses and FS DPI versus Fp MDPI (p < 0.0001), and with FS MDPI 100/50 μg versus FS DPI (least squares [LS] mean, 57.88 mL; p = 0.0017).",Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216137/),ml,57.88,104453,DB01001,Salbutamol
,27216137,AUC0-12,"FEV1 AUC0-12 trended toward higher efficacy with FS MDPI 100/25 μg (LS mean, 34.14 mL; p = 0.0624) and was comparable with FS MDPI 100/12.5 μg (LS mean, 3.42 mL; p = 0.8503) versus FS DPI.",Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216137/),ml,34.14,104454,DB01001,Salbutamol
,27216137,AUC0-12,"FEV1 AUC0-12 trended toward higher efficacy with FS MDPI 100/25 μg (LS mean, 34.14 mL; p = 0.0624) and was comparable with FS MDPI 100/12.5 μg (LS mean, 3.42 mL; p = 0.8503) versus FS DPI.",Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216137/),ml,3.42,104455,DB01001,Salbutamol
,30296863,zeta potential,"Optimized liposomal formulation exhibited an average size of about 167.2 ± 0.170 nm, with 80.68 ± 0.74% drug entrapment, and 9.74 ± 1.10 mV zeta potential.",Lung delivery of nanoliposomal salbutamol sulfate dry powder inhalation for facilitated asthma therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30296863/),,80,107003,DB01001,Salbutamol
,30296863,zeta potential,"Optimized liposomal formulation exhibited an average size of about 167.2 ± 0.170 nm, with 80.68 ± 0.74% drug entrapment, and 9.74 ± 1.10 mV zeta potential.",Lung delivery of nanoliposomal salbutamol sulfate dry powder inhalation for facilitated asthma therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30296863/),m,9.74,107004,DB01001,Salbutamol
,10030766,apparent volume of distribution,"The apparent volume of distribution of albuterol was significantly higher in men than in women (631+/-171 and 510+/-109 L, respectively, p<0.05).",Effects of gender and race on albuterol pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10030766/),l,631,110100,DB01001,Salbutamol
,10030766,apparent volume of distribution,"The apparent volume of distribution of albuterol was significantly higher in men than in women (631+/-171 and 510+/-109 L, respectively, p<0.05).",Effects of gender and race on albuterol pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10030766/),l,510,110101,DB01001,Salbutamol
,10030766,maximum concentration,"Consequently, the maximum concentration was lower in men than women (10.3+/-2.1 and 12.0+/-1.9 ng/ml, respectively, p<0.05).",Effects of gender and race on albuterol pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10030766/),[ng] / [ml],10.3,110102,DB01001,Salbutamol
,10030766,maximum concentration,"Consequently, the maximum concentration was lower in men than women (10.3+/-2.1 and 12.0+/-1.9 ng/ml, respectively, p<0.05).",Effects of gender and race on albuterol pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10030766/),[ng] / [ml],12.0,110103,DB01001,Salbutamol
,10030766,Elimination rates,"Elimination rates were 0.136+/-0.008 and 0.160+0.012 hour(-1), respectively (p<0.10).",Effects of gender and race on albuterol pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10030766/),1/[hour],0.136,110104,DB01001,Salbutamol
,10030766,Elimination rates,"Elimination rates were 0.136+/-0.008 and 0.160+0.012 hour(-1), respectively (p<0.10).",Effects of gender and race on albuterol pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10030766/),1/[hour],0.160,110105,DB01001,Salbutamol
,9431837,time from,The time from drug administration to delivery was different for each woman (27-105 min).,Transplacental distribution of salbutamol enantiomers at Caesarian section. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431837/),min,27-105,111848,DB01001,Salbutamol
,12580109,flow-rate,"The mobile phase consisted of acetonitrile-water-formic acid (20:80:1), at a flow-rate of 0.4 mL.min-1.",[Rapid analysis of terbutaline by combined solid phase extraction/liquid chromatography tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580109/),[ml] / [min],0.4,112113,DB01001,Salbutamol
,12580109,ch,The chromatographic analysis time for each sample was approximately 3.8 min.,[Rapid analysis of terbutaline by combined solid phase extraction/liquid chromatography tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580109/),min,3.8,112114,DB01001,Salbutamol
,12100764,T(max),"The parameters for salbutamol inhaled and orally administered were as following: T(max) (0.22+/-0.07) and (1.8+/-0.6) h, C(max) (3.4+/-1.1) and (3.9+/-1.4) microg/L, T(1/2) (4.5+/-1.5) and (4.6+/-1.1) h, AUC0-20 min (0.9+/-0.3) and (0.16+/-0.10) microg x h x L(-1), respectively.",Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100764/),h,0.22,112188,DB01001,Salbutamol
,12100764,T(max),"The parameters for salbutamol inhaled and orally administered were as following: T(max) (0.22+/-0.07) and (1.8+/-0.6) h, C(max) (3.4+/-1.1) and (3.9+/-1.4) microg/L, T(1/2) (4.5+/-1.5) and (4.6+/-1.1) h, AUC0-20 min (0.9+/-0.3) and (0.16+/-0.10) microg x h x L(-1), respectively.",Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100764/),h,1.8,112189,DB01001,Salbutamol
,12100764,C(max),"The parameters for salbutamol inhaled and orally administered were as following: T(max) (0.22+/-0.07) and (1.8+/-0.6) h, C(max) (3.4+/-1.1) and (3.9+/-1.4) microg/L, T(1/2) (4.5+/-1.5) and (4.6+/-1.1) h, AUC0-20 min (0.9+/-0.3) and (0.16+/-0.10) microg x h x L(-1), respectively.",Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100764/),[μg] / [l],3.4,112190,DB01001,Salbutamol
,12100764,C(max),"The parameters for salbutamol inhaled and orally administered were as following: T(max) (0.22+/-0.07) and (1.8+/-0.6) h, C(max) (3.4+/-1.1) and (3.9+/-1.4) microg/L, T(1/2) (4.5+/-1.5) and (4.6+/-1.1) h, AUC0-20 min (0.9+/-0.3) and (0.16+/-0.10) microg x h x L(-1), respectively.",Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100764/),[μg] / [l],3.9,112191,DB01001,Salbutamol
,12100764,T(1/2),"The parameters for salbutamol inhaled and orally administered were as following: T(max) (0.22+/-0.07) and (1.8+/-0.6) h, C(max) (3.4+/-1.1) and (3.9+/-1.4) microg/L, T(1/2) (4.5+/-1.5) and (4.6+/-1.1) h, AUC0-20 min (0.9+/-0.3) and (0.16+/-0.10) microg x h x L(-1), respectively.",Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100764/),h,4.5,112192,DB01001,Salbutamol
,12100764,T(1/2),"The parameters for salbutamol inhaled and orally administered were as following: T(max) (0.22+/-0.07) and (1.8+/-0.6) h, C(max) (3.4+/-1.1) and (3.9+/-1.4) microg/L, T(1/2) (4.5+/-1.5) and (4.6+/-1.1) h, AUC0-20 min (0.9+/-0.3) and (0.16+/-0.10) microg x h x L(-1), respectively.",Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100764/),h,4.6,112193,DB01001,Salbutamol
,12100764,AUC0-20 min,"The parameters for salbutamol inhaled and orally administered were as following: T(max) (0.22+/-0.07) and (1.8+/-0.6) h, C(max) (3.4+/-1.1) and (3.9+/-1.4) microg/L, T(1/2) (4.5+/-1.5) and (4.6+/-1.1) h, AUC0-20 min (0.9+/-0.3) and (0.16+/-0.10) microg x h x L(-1), respectively.",Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100764/),[h·μg] / [l],0.9,112194,DB01001,Salbutamol
,12100764,AUC0-20 min,"The parameters for salbutamol inhaled and orally administered were as following: T(max) (0.22+/-0.07) and (1.8+/-0.6) h, C(max) (3.4+/-1.1) and (3.9+/-1.4) microg/L, T(1/2) (4.5+/-1.5) and (4.6+/-1.1) h, AUC0-20 min (0.9+/-0.3) and (0.16+/-0.10) microg x h x L(-1), respectively.",Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100764/),[h·μg] / [l],0.16,112195,DB01001,Salbutamol
,12100764,relative bioavailability,The relative bioavailability of salbutamol MDI was 57 %+/-24 % compared with oral solution.,Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100764/),%,57,112196,DB01001,Salbutamol
,9349929,Cmax,Significant differences in lung delivery were found between the Diskus and the Turbuhaler for salbutamol Cmax 3.21 vs 4.04 ng.,Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349929/),ng,3.21,112795,DB01001,Salbutamol
,9349929,Cmax,Significant differences in lung delivery were found between the Diskus and the Turbuhaler for salbutamol Cmax 3.21 vs 4.04 ng.,Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349929/),ng,4.04,112796,DB01001,Salbutamol
,9349929,Cav,"ml-1, respectively and Cav 2.65 vs 3.73 ng.",Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349929/),ng,2.65,112797,DB01001,Salbutamol
,9349929,Cav,"ml-1, respectively and Cav 2.65 vs 3.73 ng.",Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349929/),ng,3.73,112798,DB01001,Salbutamol
,19537837,AUC(0-3),"At 6 weeks, FEV(1) AUC(0-3) was significantly greater in the formoterol group compared with the placebo group (1.57 vs 1.38 L [p < 0.0001]).","Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537837/),l,1.57,114020,DB01001,Salbutamol
,19537837,AUC(0-3),"At 6 weeks, FEV(1) AUC(0-3) was significantly greater in the formoterol group compared with the placebo group (1.57 vs 1.38 L [p < 0.0001]).","Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537837/),l,1.38,114021,DB01001,Salbutamol
,26704899,maximum urine salbutamol concentration,The maximum urine salbutamol concentration value peaked after the cycling effort and was 510 ng.,Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26704899/),ng,510,115809,DB01001,Salbutamol
,9649352,peak plasma level,The mean peak plasma level was 1469 +/- 410 pg/mL.,"Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649352/),[pg] / [ml],1469,118079,DB01001,Salbutamol
,9649352,half-life of distribution,The mean half-life of distribution was 17.9 +/- 8.2 min.,"Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649352/),min,17.9,118080,DB01001,Salbutamol
,9649352,half-life of elimination,The mean half-life of elimination was 4.4 +/- 1.5 h.,"Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649352/),h,4.4,118081,DB01001,Salbutamol
,9649352,peak concentration,"Female subjects achieved peak concentration more rapidly than male subjects (10.4 vs 14.8 min, p = 0.01) and had a higher mean peak concentration (1778 vs 1159 pg/mL, p = 0.04).","Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649352/),min,10.4,118082,DB01001,Salbutamol
,9649352,peak concentration,"Female subjects achieved peak concentration more rapidly than male subjects (10.4 vs 14.8 min, p = 0.01) and had a higher mean peak concentration (1778 vs 1159 pg/mL, p = 0.04).","Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649352/),min,14.8,118083,DB01001,Salbutamol
,9649352,peak concentration,"Female subjects achieved peak concentration more rapidly than male subjects (10.4 vs 14.8 min, p = 0.01) and had a higher mean peak concentration (1778 vs 1159 pg/mL, p = 0.04).","Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649352/),[pg] / [ml],1778,118084,DB01001,Salbutamol
,9649352,peak concentration,"Female subjects achieved peak concentration more rapidly than male subjects (10.4 vs 14.8 min, p = 0.01) and had a higher mean peak concentration (1778 vs 1159 pg/mL, p = 0.04).","Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649352/),[pg] / [ml],1159,118085,DB01001,Salbutamol
,12959292,t(max),"Values for t(max) (min), median and range: MA 5 (5-10) vs MDI 5 (5-10); and AUC 0-60, (ng ml(-1) min, mean and 95% CI for difference between MA and MDI): 69 (-5-143), were not significantly different between the two devices.",Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959292/),min,5,118668,DB01001,Salbutamol
,19000365,USAL0.5,"The mean (s.d.) USAL0.5 values following MDI, VOL and AERO (n = 13 volunteers) were 5.7 (1.9), 16.4 (8.2) and 14.8 (7.4) microg, respectively.",Salbutamol relative lung and systemic bioavailability of large and small spacers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000365/),μg,5.7,124086,DB01001,Salbutamol
,19000365,USAL0.5,"The mean (s.d.) USAL0.5 values following MDI, VOL and AERO (n = 13 volunteers) were 5.7 (1.9), 16.4 (8.2) and 14.8 (7.4) microg, respectively.",Salbutamol relative lung and systemic bioavailability of large and small spacers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000365/),μg,16.4,124087,DB01001,Salbutamol
,19000365,USAL0.5,"The mean (s.d.) USAL0.5 values following MDI, VOL and AERO (n = 13 volunteers) were 5.7 (1.9), 16.4 (8.2) and 14.8 (7.4) microg, respectively.",Salbutamol relative lung and systemic bioavailability of large and small spacers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000365/),μg,14.8,124088,DB01001,Salbutamol
,19000365,aerodynamic diameter,"The values for the mean (s.d.) fine particle dose of two 100-microg doses emitted from MDI, VOL and AERO were 83.0 (6.8), 83.6 (4.6) and 73.6 (2.9) microg and the mass median aerodynamic diameters were 2.7 (0.03), 2.8 (0.07) and 2.9 (0.10) mum, respectively.",Salbutamol relative lung and systemic bioavailability of large and small spacers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000365/),mum,2.7,124089,DB01001,Salbutamol
,19000365,aerodynamic diameter,"The values for the mean (s.d.) fine particle dose of two 100-microg doses emitted from MDI, VOL and AERO were 83.0 (6.8), 83.6 (4.6) and 73.6 (2.9) microg and the mass median aerodynamic diameters were 2.7 (0.03), 2.8 (0.07) and 2.9 (0.10) mum, respectively.",Salbutamol relative lung and systemic bioavailability of large and small spacers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000365/),mum,2.8,124090,DB01001,Salbutamol
,19000365,aerodynamic diameter,"The values for the mean (s.d.) fine particle dose of two 100-microg doses emitted from MDI, VOL and AERO were 83.0 (6.8), 83.6 (4.6) and 73.6 (2.9) microg and the mass median aerodynamic diameters were 2.7 (0.03), 2.8 (0.07) and 2.9 (0.10) mum, respectively.",Salbutamol relative lung and systemic bioavailability of large and small spacers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000365/),mum,2.9,124091,DB01001,Salbutamol
,24692077,Cmax,"Observed Cmax of R- and S-salbutamol [mean (SD)] was 0.64 (0.30) ng/mL and 1.32 (0.98) ng/mL, respectively.",SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692077/),[ng] / [ml],0.64,130576,DB01001,Salbutamol
,24692077,Cmax,"Observed Cmax of R- and S-salbutamol [mean (SD)] was 0.64 (0.30) ng/mL and 1.32 (0.98) ng/mL, respectively.",SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692077/),[ng] / [ml],1.32,130577,DB01001,Salbutamol
,24692077,t1/2,The mean t1/2 of R- and S-salbutamol was estimated at 2.94 (1.17) h and 7.86 (6.14) h respectively.,SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692077/),h,2.94,130578,DB01001,Salbutamol
,24692077,t1/2,The mean t1/2 of R- and S-salbutamol was estimated at 2.94 (1.17) h and 7.86 (6.14) h respectively.,SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692077/),h,7.86,130579,DB01001,Salbutamol
,24692077,AUC0-4h,The AUC0-4h of R- and S-salbutamol was 14.0 (6.8) and 38.3 (19.5) ng/mL.h respectively.,SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692077/),[ng] / [h·ml],14.0,130580,DB01001,Salbutamol
,24692077,AUC0-4h,The AUC0-4h of R- and S-salbutamol was 14.0 (6.8) and 38.3 (19.5) ng/mL.h respectively.,SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692077/),[ng] / [h·ml],38.3,130581,DB01001,Salbutamol
,17329898,AUC(0-24),"The pharmacokinetics parameters of pulsatile-release salbutamol sulfate and reference tablet were AUC(0-24) (ng.h/ml) 1031.8+/-123.1, 1112.6+/-118.24, Cmax (ng/ml) 172.4+/-21.4, 179.3+/-26.1, Tmax (h) 3.8+/-0.6, 1.5+/-0.5, Tlag (h) 2.7+/-0.5, 0.3+/-0.2.",The investigation of the pharmacokinetics of pulsatile-release salbutamol sulfate with pH-sensitive ion exchange resin as the carriers in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329898/),[h·ng] / [ml],1031.8,133840,DB01001,Salbutamol
,17329898,AUC(0-24),"The pharmacokinetics parameters of pulsatile-release salbutamol sulfate and reference tablet were AUC(0-24) (ng.h/ml) 1031.8+/-123.1, 1112.6+/-118.24, Cmax (ng/ml) 172.4+/-21.4, 179.3+/-26.1, Tmax (h) 3.8+/-0.6, 1.5+/-0.5, Tlag (h) 2.7+/-0.5, 0.3+/-0.2.",The investigation of the pharmacokinetics of pulsatile-release salbutamol sulfate with pH-sensitive ion exchange resin as the carriers in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329898/),[h·ng] / [ml],1112.6,133841,DB01001,Salbutamol
,17329898,Cmax,"The pharmacokinetics parameters of pulsatile-release salbutamol sulfate and reference tablet were AUC(0-24) (ng.h/ml) 1031.8+/-123.1, 1112.6+/-118.24, Cmax (ng/ml) 172.4+/-21.4, 179.3+/-26.1, Tmax (h) 3.8+/-0.6, 1.5+/-0.5, Tlag (h) 2.7+/-0.5, 0.3+/-0.2.",The investigation of the pharmacokinetics of pulsatile-release salbutamol sulfate with pH-sensitive ion exchange resin as the carriers in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329898/),[ng] / [ml],172.4,133842,DB01001,Salbutamol
,17329898,Cmax,"The pharmacokinetics parameters of pulsatile-release salbutamol sulfate and reference tablet were AUC(0-24) (ng.h/ml) 1031.8+/-123.1, 1112.6+/-118.24, Cmax (ng/ml) 172.4+/-21.4, 179.3+/-26.1, Tmax (h) 3.8+/-0.6, 1.5+/-0.5, Tlag (h) 2.7+/-0.5, 0.3+/-0.2.",The investigation of the pharmacokinetics of pulsatile-release salbutamol sulfate with pH-sensitive ion exchange resin as the carriers in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329898/),[ng] / [ml],179.3,133843,DB01001,Salbutamol
,17329898,Tmax,"The pharmacokinetics parameters of pulsatile-release salbutamol sulfate and reference tablet were AUC(0-24) (ng.h/ml) 1031.8+/-123.1, 1112.6+/-118.24, Cmax (ng/ml) 172.4+/-21.4, 179.3+/-26.1, Tmax (h) 3.8+/-0.6, 1.5+/-0.5, Tlag (h) 2.7+/-0.5, 0.3+/-0.2.",The investigation of the pharmacokinetics of pulsatile-release salbutamol sulfate with pH-sensitive ion exchange resin as the carriers in beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329898/),h,3.8,133844,DB01001,Salbutamol
,17329898,Tmax,"The pharmacokinetics parameters of pulsatile-release salbutamol sulfate and reference tablet were AUC(0-24) (ng.h/ml) 1031.8+/-123.1, 1112.6+/-118.24, Cmax (ng/ml) 172.4+/-21.4, 179.3+/-26.1, Tmax (h) 3.8+/-0.6, 1.5+/-0.5, Tlag (h) 2.7+/-0.5, 0.3+/-0.2.",The investigation of the pharmacokinetics of pulsatile-release salbutamol sulfate with pH-sensitive ion exchange resin as the carriers in beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329898/),h,1.5,133845,DB01001,Salbutamol
,17329898,Tlag,"The pharmacokinetics parameters of pulsatile-release salbutamol sulfate and reference tablet were AUC(0-24) (ng.h/ml) 1031.8+/-123.1, 1112.6+/-118.24, Cmax (ng/ml) 172.4+/-21.4, 179.3+/-26.1, Tmax (h) 3.8+/-0.6, 1.5+/-0.5, Tlag (h) 2.7+/-0.5, 0.3+/-0.2.",The investigation of the pharmacokinetics of pulsatile-release salbutamol sulfate with pH-sensitive ion exchange resin as the carriers in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329898/),h,2.7,133846,DB01001,Salbutamol
,17329898,Tlag,"The pharmacokinetics parameters of pulsatile-release salbutamol sulfate and reference tablet were AUC(0-24) (ng.h/ml) 1031.8+/-123.1, 1112.6+/-118.24, Cmax (ng/ml) 172.4+/-21.4, 179.3+/-26.1, Tmax (h) 3.8+/-0.6, 1.5+/-0.5, Tlag (h) 2.7+/-0.5, 0.3+/-0.2.",The investigation of the pharmacokinetics of pulsatile-release salbutamol sulfate with pH-sensitive ion exchange resin as the carriers in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329898/),h,0.3,133847,DB01001,Salbutamol
,10587476,AUC,No significant differences in pharmacokinetics of (R)-salbutamol given as either (R)- or (RS)-salbutamol were found with AUC values of 11.90 +/- 4.37 and 11. 47 +/- 2.88 ng.h/ml.,Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587476/),[h·ng] / [ml],11.90,134118,DB01001,Salbutamol
,10587476,AUC,No significant differences in pharmacokinetics of (R)-salbutamol given as either (R)- or (RS)-salbutamol were found with AUC values of 11.90 +/- 4.37 and 11. 47 +/- 2.88 ng.h/ml.,Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587476/),[h·ng] / [ml],11. 47,134119,DB01001,Salbutamol
,10587476,t(max),The t(max)of about 2 h reflected serial dosing rather than delayed absorption.,Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587476/),h,2,134120,DB01001,Salbutamol
,10587476,t(1/2),The t(1/2)averaged about 3.5 h.,Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587476/),h,3.5,134121,DB01001,Salbutamol
,10587476,AUC,The (S)-salbutamol showed AUC of 48.46 +/- 12.11 ng.h/ml with a t(1/2)of about 5 h.,Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587476/),[h·ng] / [ml],48.46,134122,DB01001,Salbutamol
,10587476,t(1/2),The (S)-salbutamol showed AUC of 48.46 +/- 12.11 ng.h/ml with a t(1/2)of about 5 h.,Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587476/),h,5,134123,DB01001,Salbutamol
,8554933,peak plasma concentrations,"For instance, peak plasma concentrations of salbutamol were 10.5 +/- 2.6 (mean +/- s.d.) and 10.2 +/- 2.9 ng ml-1 (NS), and the area under salbutamol plasma concentrations as a function of time (AUC (0, 7 h)) was 43.0 +/- 9.3 ng ml-1 h and 43.3 +/- 12.7 ng ml-1 h (NS) in CF patients and in healthy subjects, respectively.",Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554933/),[ng] / [ml],10.5,135313,DB01001,Salbutamol
,8554933,peak plasma concentrations,"For instance, peak plasma concentrations of salbutamol were 10.5 +/- 2.6 (mean +/- s.d.) and 10.2 +/- 2.9 ng ml-1 (NS), and the area under salbutamol plasma concentrations as a function of time (AUC (0, 7 h)) was 43.0 +/- 9.3 ng ml-1 h and 43.3 +/- 12.7 ng ml-1 h (NS) in CF patients and in healthy subjects, respectively.",Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554933/),[ng] / [ml],10.2,135314,DB01001,Salbutamol
,8554933,"area under salbutamol plasma concentrations as a function of time (AUC (0, 7 h))","For instance, peak plasma concentrations of salbutamol were 10.5 +/- 2.6 (mean +/- s.d.) and 10.2 +/- 2.9 ng ml-1 (NS), and the area under salbutamol plasma concentrations as a function of time (AUC (0, 7 h)) was 43.0 +/- 9.3 ng ml-1 h and 43.3 +/- 12.7 ng ml-1 h (NS) in CF patients and in healthy subjects, respectively.",Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554933/),[h·ng] / [ml],43.0,135315,DB01001,Salbutamol
,8554933,"area under salbutamol plasma concentrations as a function of time (AUC (0, 7 h))","For instance, peak plasma concentrations of salbutamol were 10.5 +/- 2.6 (mean +/- s.d.) and 10.2 +/- 2.9 ng ml-1 (NS), and the area under salbutamol plasma concentrations as a function of time (AUC (0, 7 h)) was 43.0 +/- 9.3 ng ml-1 h and 43.3 +/- 12.7 ng ml-1 h (NS) in CF patients and in healthy subjects, respectively.",Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554933/),[h·ng] / [ml],43.3,135316,DB01001,Salbutamol
,8554933,heart rate,"3. Salbutamol did not elicit bronchodilation in CF patients, but increased heart rate from 77 +/- 2 to 103 +/- 3 beats min-1 (P < 0.05).",Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554933/),[beats] / [min],77,135317,DB01001,Salbutamol
,8554933,heart rate,"3. Salbutamol did not elicit bronchodilation in CF patients, but increased heart rate from 77 +/- 2 to 103 +/- 3 beats min-1 (P < 0.05).",Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554933/),[beats] / [min],103,135318,DB01001,Salbutamol
,15234788,Cmax,"The result showed that Cmax +/- S.D. observed were 12.96 +/- 2.11, 14.78 +/- 2.33, 10.02 +/- 1.42 and 11.51 +/- 1.22 ng ml(-1) for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),[ng] / [ml],12.96,135616,DB01001,Salbutamol
,15234788,Cmax,"The result showed that Cmax +/- S.D. observed were 12.96 +/- 2.11, 14.78 +/- 2.33, 10.02 +/- 1.42 and 11.51 +/- 1.22 ng ml(-1) for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),[ng] / [ml],14.78,135617,DB01001,Salbutamol
,15234788,Cmax,"The result showed that Cmax +/- S.D. observed were 12.96 +/- 2.11, 14.78 +/- 2.33, 10.02 +/- 1.42 and 11.51 +/- 1.22 ng ml(-1) for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),[ng] / [ml],10.02,135618,DB01001,Salbutamol
,15234788,Cmax,"The result showed that Cmax +/- S.D. observed were 12.96 +/- 2.11, 14.78 +/- 2.33, 10.02 +/- 1.42 and 11.51 +/- 1.22 ng ml(-1) for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),[ng] / [ml],11.51,135619,DB01001,Salbutamol
,15234788,Tmax,"The Tmax +/- S.D. were found to be 1.91 +/- 0.20, 1.83 +/- 0.26, 2.50 +/- 0.00 and 2.67 +/- 0.24 h for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),h,1.91,135620,DB01001,Salbutamol
,15234788,Tmax,"The Tmax +/- S.D. were found to be 1.91 +/- 0.20, 1.83 +/- 0.26, 2.50 +/- 0.00 and 2.67 +/- 0.24 h for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),h,1.83,135621,DB01001,Salbutamol
,15234788,Tmax,"The Tmax +/- S.D. were found to be 1.91 +/- 0.20, 1.83 +/- 0.26, 2.50 +/- 0.00 and 2.67 +/- 0.24 h for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),h,2.50,135622,DB01001,Salbutamol
,15234788,Tmax,"The Tmax +/- S.D. were found to be 1.91 +/- 0.20, 1.83 +/- 0.26, 2.50 +/- 0.00 and 2.67 +/- 0.24 h for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),h,2.67,135623,DB01001,Salbutamol
,15234788,AUC,"AUC +/- S.D. values were 40.25 +/- 1.88, 42.16 +/- 1.55, 28.62 +/- 1.98 and 37.63 +/- 1.44 ng h per ml for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),[h·ng] / [ml],40.25,135624,DB01001,Salbutamol
,15234788,AUC,"AUC +/- S.D. values were 40.25 +/- 1.88, 42.16 +/- 1.55, 28.62 +/- 1.98 and 37.63 +/- 1.44 ng h per ml for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),[h·ng] / [ml],42.16,135625,DB01001,Salbutamol
,15234788,AUC,"AUC +/- S.D. values were 40.25 +/- 1.88, 42.16 +/- 1.55, 28.62 +/- 1.98 and 37.63 +/- 1.44 ng h per ml for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),[h·ng] / [ml],28.62,135626,DB01001,Salbutamol
,15234788,AUC,"AUC +/- S.D. values were 40.25 +/- 1.88, 42.16 +/- 1.55, 28.62 +/- 1.98 and 37.63 +/- 1.44 ng h per ml for F1, F2, F3 and F4, respectively.",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),[h·ng] / [ml],37.63,135627,DB01001,Salbutamol
,15234788,relative bioavailabilities,"The relative bioavailabilities of the investigated formulations were 112.04, 106.96 and 76.06 for formula F2, F1 and F3, respectively, when compared with the oral preparation (F4).",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),,112.04,135628,DB01001,Salbutamol
,15234788,relative bioavailabilities,"The relative bioavailabilities of the investigated formulations were 112.04, 106.96 and 76.06 for formula F2, F1 and F3, respectively, when compared with the oral preparation (F4).",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),,106.96,135629,DB01001,Salbutamol
,15234788,relative bioavailabilities,"The relative bioavailabilities of the investigated formulations were 112.04, 106.96 and 76.06 for formula F2, F1 and F3, respectively, when compared with the oral preparation (F4).",Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234788/),,76.06,135630,DB01001,Salbutamol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,3.07,136756,DB01001,Salbutamol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,6.21,136757,DB01001,Salbutamol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,0.84,136758,DB01001,Salbutamol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,1.50,136759,DB01001,Salbutamol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136760,DB01001,Salbutamol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136761,DB01001,Salbutamol
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136762,DB01001,Salbutamol
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136763,DB01001,Salbutamol
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,15.5,136764,DB01001,Salbutamol
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,50.8,136765,DB01001,Salbutamol
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,4.41,136766,DB01001,Salbutamol
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,12.78,136767,DB01001,Salbutamol
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,1.08,136768,DB01001,Salbutamol
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,0.09,136769,DB01001,Salbutamol
,28033454,Maximum rac-salmeterol urine concentrations,"Maximum rac-salmeterol urine concentrations were obtained at 2 h for both doses with medians of 0.084 ng/mL after the 50 µg dose and 2.1 ng/mL after the 200 µg dose, with an individual maximum of 5.7 ng/mL.",Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28033454/),[ng] / [ml],0.084,140351,DB01001,Salbutamol
,28033454,Maximum rac-salmeterol urine concentrations,"Maximum rac-salmeterol urine concentrations were obtained at 2 h for both doses with medians of 0.084 ng/mL after the 50 µg dose and 2.1 ng/mL after the 200 µg dose, with an individual maximum of 5.7 ng/mL.",Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28033454/),[ng] / [ml],2.1,140352,DB01001,Salbutamol
,28033454,maximum,"Maximum rac-salmeterol urine concentrations were obtained at 2 h for both doses with medians of 0.084 ng/mL after the 50 µg dose and 2.1 ng/mL after the 200 µg dose, with an individual maximum of 5.7 ng/mL.",Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28033454/),[ng] / [ml],5.7,140353,DB01001,Salbutamol
,6520178,minimum detection limit,The minimum detection limit was 400 pg/ml from a 0.5-ml sample of serum.,Determination of salbutamol in human serum by reversed-phase high-performance liquid chromatography with amperometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520178/),[pg] / [ml],400,141964,DB01001,Salbutamol
,1635728,rate,"We used three different rates of continuous infusion: a low rate of 3.33 micrograms/minute (20 subjects), an intermediate rate of 6.66 micrograms/minute (four subjects), and a high rate of 9.99 micrograms/minute (five subjects).",Pharmacokinetics of salbutamol in the pregnant woman after subcutaneous administration with a portable pump. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635728/),[μg] / [min],3.33,144182,DB01001,Salbutamol
,1635728,rate,"We used three different rates of continuous infusion: a low rate of 3.33 micrograms/minute (20 subjects), an intermediate rate of 6.66 micrograms/minute (four subjects), and a high rate of 9.99 micrograms/minute (five subjects).",Pharmacokinetics of salbutamol in the pregnant woman after subcutaneous administration with a portable pump. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635728/),[μg] / [min],6.66,144183,DB01001,Salbutamol
,1635728,rate,"We used three different rates of continuous infusion: a low rate of 3.33 micrograms/minute (20 subjects), an intermediate rate of 6.66 micrograms/minute (four subjects), and a high rate of 9.99 micrograms/minute (five subjects).",Pharmacokinetics of salbutamol in the pregnant woman after subcutaneous administration with a portable pump. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635728/),[μg] / [min],9.99,144184,DB01001,Salbutamol
,1635728,concentrations,"Plasma salbutamol concentrations after 48 hours of subcutaneous infusion increased almost linearly with the rate of infusion: 6.29 +/- 1.58, 15.5 +/- 1.0, and 21.7 +/- 4.26 ng/mL in the low-, intermediate-, and high-rate groups, respectively (P less than .001 between the three groups).",Pharmacokinetics of salbutamol in the pregnant woman after subcutaneous administration with a portable pump. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635728/),[ng] / [ml],6.29,144185,DB01001,Salbutamol
,1635728,concentrations,"Plasma salbutamol concentrations after 48 hours of subcutaneous infusion increased almost linearly with the rate of infusion: 6.29 +/- 1.58, 15.5 +/- 1.0, and 21.7 +/- 4.26 ng/mL in the low-, intermediate-, and high-rate groups, respectively (P less than .001 between the three groups).",Pharmacokinetics of salbutamol in the pregnant woman after subcutaneous administration with a portable pump. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635728/),[ng] / [ml],15.5,144186,DB01001,Salbutamol
,1635728,concentrations,"Plasma salbutamol concentrations after 48 hours of subcutaneous infusion increased almost linearly with the rate of infusion: 6.29 +/- 1.58, 15.5 +/- 1.0, and 21.7 +/- 4.26 ng/mL in the low-, intermediate-, and high-rate groups, respectively (P less than .001 between the three groups).",Pharmacokinetics of salbutamol in the pregnant woman after subcutaneous administration with a portable pump. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635728/),[ng] / [ml],21.7,144187,DB01001,Salbutamol
,1635728,maximum plasma concentrations,"After bolus injection, maximum plasma concentrations were significantly different between the three groups (P less than .001) and from their respective baseline values (P less than .001): 8.33 +/- 1.9, 18.85 +/- 2.0, and 25.86 +/- 4.8 ng/mL in the low-, intermediate-, and high-rate groups, respectively.",Pharmacokinetics of salbutamol in the pregnant woman after subcutaneous administration with a portable pump. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635728/),[ng] / [ml],8.33,144188,DB01001,Salbutamol
,1635728,maximum plasma concentrations,"After bolus injection, maximum plasma concentrations were significantly different between the three groups (P less than .001) and from their respective baseline values (P less than .001): 8.33 +/- 1.9, 18.85 +/- 2.0, and 25.86 +/- 4.8 ng/mL in the low-, intermediate-, and high-rate groups, respectively.",Pharmacokinetics of salbutamol in the pregnant woman after subcutaneous administration with a portable pump. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635728/),[ng] / [ml],18.85,144189,DB01001,Salbutamol
,1635728,maximum plasma concentrations,"After bolus injection, maximum plasma concentrations were significantly different between the three groups (P less than .001) and from their respective baseline values (P less than .001): 8.33 +/- 1.9, 18.85 +/- 2.0, and 25.86 +/- 4.8 ng/mL in the low-, intermediate-, and high-rate groups, respectively.",Pharmacokinetics of salbutamol in the pregnant woman after subcutaneous administration with a portable pump. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635728/),[ng] / [ml],25.86,144190,DB01001,Salbutamol
,8100506,bioavailability,"Since IA salbutamol administration generated 100% bioavailability (F), AUCIA was used as a reference for comparison.",Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100506/),,100,154873,DB01001,Salbutamol
,8100506,F,"Salbutamol F values for the ID, IP, IV, and ET routes were 0.013, 0.15, 0.53, and 0.53, respectively.",Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100506/),,0.013,154874,DB01001,Salbutamol
,8100506,F,"Salbutamol F values for the ID, IP, IV, and ET routes were 0.013, 0.15, 0.53, and 0.53, respectively.",Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100506/),,0.15,154875,DB01001,Salbutamol
,8100506,F,"Salbutamol F values for the ID, IP, IV, and ET routes were 0.013, 0.15, 0.53, and 0.53, respectively.",Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100506/),,0.53,154876,DB01001,Salbutamol
,8100506,ratio of the AUC,"The mean ratio of the AUC of the metabolite (AUCM) over the AUC of the parent compound was 704 +/- 77 for the ID, compared with 83 +/- 12 for the IP, 11 +/- 1 for the IV, 1.7 +/- 0.3 for the ET routes, and 4 +/- 1 for the IA routes.",Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100506/),,704,154877,DB01001,Salbutamol
,8100506,ratio of the AUC,"The mean ratio of the AUC of the metabolite (AUCM) over the AUC of the parent compound was 704 +/- 77 for the ID, compared with 83 +/- 12 for the IP, 11 +/- 1 for the IV, 1.7 +/- 0.3 for the ET routes, and 4 +/- 1 for the IA routes.",Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100506/),,83,154878,DB01001,Salbutamol
,8100506,ratio of the AUC,"The mean ratio of the AUC of the metabolite (AUCM) over the AUC of the parent compound was 704 +/- 77 for the ID, compared with 83 +/- 12 for the IP, 11 +/- 1 for the IV, 1.7 +/- 0.3 for the ET routes, and 4 +/- 1 for the IA routes.",Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100506/),,11,154879,DB01001,Salbutamol
,8100506,ratio of the AUC,"The mean ratio of the AUC of the metabolite (AUCM) over the AUC of the parent compound was 704 +/- 77 for the ID, compared with 83 +/- 12 for the IP, 11 +/- 1 for the IV, 1.7 +/- 0.3 for the ET routes, and 4 +/- 1 for the IA routes.",Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100506/),,1.7,154880,DB01001,Salbutamol
,8100506,ratio of the AUC,"The mean ratio of the AUC of the metabolite (AUCM) over the AUC of the parent compound was 704 +/- 77 for the ID, compared with 83 +/- 12 for the IP, 11 +/- 1 for the IV, 1.7 +/- 0.3 for the ET routes, and 4 +/- 1 for the IA routes.",Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100506/),,4,154881,DB01001,Salbutamol
,10340917,area under FEV1,"Albuterol-evoked FEV1 was higher and the response was more rapid in Arg16 homozygotes compared with the cohort of carriers of the Gly16 variant: Maximal percentage increase in FEV1 (%deltaFEV1), 18% versus 4.9% (P < .03); area under FEV1 albuterol concentration curve, 194%.mL/ng versus 30%.mL/ng (P < .05); initial slope (dE/dC), 1.43%.mL/ng versus 0.55%.mL/ng (P < .003).",Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10340917/),[%·ml] / [ng],194,158440,DB01001,Salbutamol
,10340917,area under FEV1,"Albuterol-evoked FEV1 was higher and the response was more rapid in Arg16 homozygotes compared with the cohort of carriers of the Gly16 variant: Maximal percentage increase in FEV1 (%deltaFEV1), 18% versus 4.9% (P < .03); area under FEV1 albuterol concentration curve, 194%.mL/ng versus 30%.mL/ng (P < .05); initial slope (dE/dC), 1.43%.mL/ng versus 0.55%.mL/ng (P < .003).",Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10340917/),[%·ml] / [ng],30,158441,DB01001,Salbutamol
,10340917,initial slope (dE/dC),"Albuterol-evoked FEV1 was higher and the response was more rapid in Arg16 homozygotes compared with the cohort of carriers of the Gly16 variant: Maximal percentage increase in FEV1 (%deltaFEV1), 18% versus 4.9% (P < .03); area under FEV1 albuterol concentration curve, 194%.mL/ng versus 30%.mL/ng (P < .05); initial slope (dE/dC), 1.43%.mL/ng versus 0.55%.mL/ng (P < .003).",Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10340917/),[%·ml] / [ng],1,158442,DB01001,Salbutamol
,10340917,initial slope (dE/dC),"Albuterol-evoked FEV1 was higher and the response was more rapid in Arg16 homozygotes compared with the cohort of carriers of the Gly16 variant: Maximal percentage increase in FEV1 (%deltaFEV1), 18% versus 4.9% (P < .03); area under FEV1 albuterol concentration curve, 194%.mL/ng versus 30%.mL/ng (P < .05); initial slope (dE/dC), 1.43%.mL/ng versus 0.55%.mL/ng (P < .003).",Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10340917/),[%·ml] / [ng],0.55,158443,DB01001,Salbutamol
,7766724,Maximum plasma concentrations,Maximum plasma concentrations attained at 1 h after dosing ranged between 35.3 and 66.8 ng ml-1 and were within the calibration range of the assay.,The determination in human plasma of 1-hydroxy-2-naphthoic acid following administration of salmeterol xinafoate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7766724/),[ng] / [ml],35.3 and 66.8,162911,DB01001,Salbutamol
,11301561,half-lives (t1/2),"Both (R)- and (S)-albuterol showed rapid absorption and biexponential decline, with half-lives (t1/2) averaging 4 and 6 hours, respectively.",Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301561/),h,4,167973,DB01001,Salbutamol
,11301561,half-lives (t1/2),"Both (R)- and (S)-albuterol showed rapid absorption and biexponential decline, with half-lives (t1/2) averaging 4 and 6 hours, respectively.",Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301561/),h,6,167974,DB01001,Salbutamol
,11301561,Emax,"The Emax for potassium change was 1.32 meq/L, with an EC50 of 0.59 and 0.94 ng/mL after administration of (R)- and (RS)-albuterol, respectively.",Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301561/),[meq] / [l],1.32,167975,DB01001,Salbutamol
,11301561,EC50,"The Emax for potassium change was 1.32 meq/L, with an EC50 of 0.59 and 0.94 ng/mL after administration of (R)- and (RS)-albuterol, respectively.",Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301561/),[ng] / [ml],0.59,167976,DB01001,Salbutamol
,11301561,EC50,"The Emax for potassium change was 1.32 meq/L, with an EC50 of 0.59 and 0.94 ng/mL after administration of (R)- and (RS)-albuterol, respectively.",Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301561/),[ng] / [ml],0.94,167977,DB01001,Salbutamol
,19874116,t(1/2),"According to the HPLC results, t(1/2) = 2.36 +/- 0.18 h and K(e) = 0.32 +/- 0.02 h(-1) for BR-AEA in rabbit plasma.",Pharmacokinetic parameters and a theoretical study about metabolism of BR-AEA (a salbutamol derivative) in rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874116/),h,2.36,169620,DB01001,Salbutamol
,19874116,K(e),"According to the HPLC results, t(1/2) = 2.36 +/- 0.18 h and K(e) = 0.32 +/- 0.02 h(-1) for BR-AEA in rabbit plasma.",Pharmacokinetic parameters and a theoretical study about metabolism of BR-AEA (a salbutamol derivative) in rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874116/),1/[h],0.32,169621,DB01001,Salbutamol
,19874116,t(1/2),"Thus, BR-AEA has a greater half-life compared with salbutamol (t(1/2) = 0.66 +/- 0.08 h).",Pharmacokinetic parameters and a theoretical study about metabolism of BR-AEA (a salbutamol derivative) in rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874116/),h,0.66,169622,DB01001,Salbutamol
,1280178,EC50,Nebulized RP 58802B produced a rapid onset and long lasting inhibition of histamine-induced bronchospasm in the anaesthetized guinea-pig (EC50 = 3.2 +/- 0.9 micrograms/ml; duration greater than 90 min).,"RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1280178/),[μg] / [ml],3.2,174504,DB01001,Salbutamol
,1280178,time to severe dyspnoea,"In conscious guinea-pigs, RP 58802B (5 or 25 mg/kg, p.o. 60 min before challenge) significantly attenuated antigen-induced dyspnoea with the time to severe dyspnoea increasing from 170 +/- 32 to 325 +/- 32 s at the higher dose of drug.","RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1280178/),s,170,174505,DB01001,Salbutamol
,1280178,time to severe dyspnoea,"In conscious guinea-pigs, RP 58802B (5 or 25 mg/kg, p.o. 60 min before challenge) significantly attenuated antigen-induced dyspnoea with the time to severe dyspnoea increasing from 170 +/- 32 to 325 +/- 32 s at the higher dose of drug.","RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1280178/),s,325,174506,DB01001,Salbutamol
,9827736,plasma levels,"At the end of treatment, the salbutamol plasma levels were 10.1+/-1.6 ng/ml for the MDI-spacer group and 14.4+/-2.3 ng/ml for the NEB group (P=.0003).",Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9827736/),[ng] / [ml],10.1,175182,DB01001,Salbutamol
,9827736,plasma levels,"At the end of treatment, the salbutamol plasma levels were 10.1+/-1.6 ng/ml for the MDI-spacer group and 14.4+/-2.3 ng/ml for the NEB group (P=.0003).",Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9827736/),[ng] / [ml],14.4,175183,DB01001,Salbutamol
,3790406,total plasma clearance,"With intravenous administration, total plasma clearance was 480 +/- 123 ml min-1, elimination half-life was 3.86 +/- 0.83 h and apparent volume of distribution was 156 +/- 381.",Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790406/),[ml] / [min],480,175839,DB01001,Salbutamol
,3790406,elimination half-life,"With intravenous administration, total plasma clearance was 480 +/- 123 ml min-1, elimination half-life was 3.86 +/- 0.83 h and apparent volume of distribution was 156 +/- 381.",Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790406/),h,3.86,175840,DB01001,Salbutamol
,3790406,apparent volume of distribution,"With intravenous administration, total plasma clearance was 480 +/- 123 ml min-1, elimination half-life was 3.86 +/- 0.83 h and apparent volume of distribution was 156 +/- 381.",Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790406/),,156,175841,DB01001,Salbutamol
,3790406,Urinary excretion,"Urinary excretion of unchanged drug and sulphate conjugate were 64.2 +/- 7.1% and 12.0 +/- 3.1% of the dose, respectively.",Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790406/),%,64.2,175842,DB01001,Salbutamol
,3790406,Urinary excretion,"Urinary excretion of unchanged drug and sulphate conjugate were 64.2 +/- 7.1% and 12.0 +/- 3.1% of the dose, respectively.",Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790406/),%,12.0,175843,DB01001,Salbutamol
,3790406,systemic availability,"With oral administration, systemic availability was 0.50 +/- 0.04, and urinary excretion of unchanged drug and sulphate conjugate were 31.8 +/- 1.9% and 48.2 +/- 7.3% of the dose, respectively.",Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790406/),,0.50,175844,DB01001,Salbutamol
,3790406,urinary excretion,"With oral administration, systemic availability was 0.50 +/- 0.04, and urinary excretion of unchanged drug and sulphate conjugate were 31.8 +/- 1.9% and 48.2 +/- 7.3% of the dose, respectively.",Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790406/),%,31.8,175845,DB01001,Salbutamol
,3790406,urinary excretion,"With oral administration, systemic availability was 0.50 +/- 0.04, and urinary excretion of unchanged drug and sulphate conjugate were 31.8 +/- 1.9% and 48.2 +/- 7.3% of the dose, respectively.",Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790406/),%,48.2,175846,DB01001,Salbutamol
,3790406,Renal clearance,"Renal clearance of salbutamol was 291 +/- 70 ml min-1 after intravenous and 272 +/- 38 ml min-1 after oral administration, while the renal clearance of the sulphate conjugate was 98.5 +/- 23.5 ml min-1 after oral administration.",Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790406/),[ml] / [min],291,175847,DB01001,Salbutamol
,3790406,Renal clearance,"Renal clearance of salbutamol was 291 +/- 70 ml min-1 after intravenous and 272 +/- 38 ml min-1 after oral administration, while the renal clearance of the sulphate conjugate was 98.5 +/- 23.5 ml min-1 after oral administration.",Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790406/),[ml] / [min],272,175848,DB01001,Salbutamol
,3790406,renal clearance,"Renal clearance of salbutamol was 291 +/- 70 ml min-1 after intravenous and 272 +/- 38 ml min-1 after oral administration, while the renal clearance of the sulphate conjugate was 98.5 +/- 23.5 ml min-1 after oral administration.",Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790406/),[ml] / [min],98.5,175849,DB01001,Salbutamol
,7874928,relative lung bioavailability,"The mean +/- SD relative lung bioavailability of albuterol to the lung following inhalation of 400 micrograms of albuterol from an MDI, the Rotahaler and Diskhaler in 10 well-trained volunteers, was 2.83 (0.78), 1.72 (0.99), and 2.64 (1.23)%, respectively, expressed as a percentage of the nominal dose.",Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874928/),%,2.83,177029,DB01001,Salbutamol
,7874928,relative lung bioavailability,"The mean +/- SD relative lung bioavailability of albuterol to the lung following inhalation of 400 micrograms of albuterol from an MDI, the Rotahaler and Diskhaler in 10 well-trained volunteers, was 2.83 (0.78), 1.72 (0.99), and 2.64 (1.23)%, respectively, expressed as a percentage of the nominal dose.",Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874928/),%,1.72,177030,DB01001,Salbutamol
,7874928,relative lung bioavailability,"The mean +/- SD relative lung bioavailability of albuterol to the lung following inhalation of 400 micrograms of albuterol from an MDI, the Rotahaler and Diskhaler in 10 well-trained volunteers, was 2.83 (0.78), 1.72 (0.99), and 2.64 (1.23)%, respectively, expressed as a percentage of the nominal dose.",Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874928/),%,2.64,177031,DB01001,Salbutamol
,7874928,relative lung bioavailability,"In nine asthmatic subjects, the relative lung bioavailability of albuterol following inhalation with the MDI and Diskhaler was 1.19 (0.79) and 2.38 (1.46)%, respectively, expressed as a percentage of the nominal dose.",Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874928/),%,1.19,177032,DB01001,Salbutamol
,7874928,relative lung bioavailability,"In nine asthmatic subjects, the relative lung bioavailability of albuterol following inhalation with the MDI and Diskhaler was 1.19 (0.79) and 2.38 (1.46)%, respectively, expressed as a percentage of the nominal dose.",Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874928/),%,2.38,177033,DB01001,Salbutamol
,10150494,t1/2,HFA134a was rapidly absorbed after inhalation with dose-related blood concentrations which declined rapidly after dosing (t1/2 = 31 min).,Clinical pharmacology of HFA134a. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10150494/),min,31,177153,DB01001,Salbutamol
,27784211,bioavailability,Salbutamol sulphate (SS) is a model short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm having poor bioavailability (50%) due to its extensive first-pass effect.,Development of Salbutamol Sulphate Sublingual Films in Pullulan Matrix for Enhanced Bioavailability & Clinical Efficacy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27784211/),%,50,177489,DB01001,Salbutamol
,27784211,disintegration time,Formula F3 containing Pullulan with Maltodextrin in a ratio 3:1 has the least disintegration time (26±2.6 seconds) and the highest dissolution rate (100%±0.5%) after four minutes.,Development of Salbutamol Sulphate Sublingual Films in Pullulan Matrix for Enhanced Bioavailability & Clinical Efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27784211/),seconds,26,177490,DB01001,Salbutamol
,27784211,tmax,Pharmacokinetic study of the optimum formula F3 in healthy human volunteers revealed a shorter tmax (0.75±0.25 hour) compared to Ventolin® tablet 2 mg (2.1±0.37 hour).,Development of Salbutamol Sulphate Sublingual Films in Pullulan Matrix for Enhanced Bioavailability & Clinical Efficacy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27784211/),h,0.75,177491,DB01001,Salbutamol
,27784211,tmax,Pharmacokinetic study of the optimum formula F3 in healthy human volunteers revealed a shorter tmax (0.75±0.25 hour) compared to Ventolin® tablet 2 mg (2.1±0.37 hour).,Development of Salbutamol Sulphate Sublingual Films in Pullulan Matrix for Enhanced Bioavailability & Clinical Efficacy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27784211/),h,2.1,177492,DB01001,Salbutamol
,3620288,total clearance,"3 By comparison with our previous study in a control group of healthy males and nonpregnant females, the total clearance of salbutamol in premature labour (501; s.d. 185 ml min-1) was similar to that in the control group (480; s.d. 123 ml min-1).",Pharmacokinetics and metabolism of salbutamol in premature labour. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620288/),[ml] / [min],501,179720,DB01001,Salbutamol
,3620288,total clearance,"3 By comparison with our previous study in a control group of healthy males and nonpregnant females, the total clearance of salbutamol in premature labour (501; s.d. 185 ml min-1) was similar to that in the control group (480; s.d. 123 ml min-1).",Pharmacokinetics and metabolism of salbutamol in premature labour. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620288/),[ml] / [min],480,179721,DB01001,Salbutamol
,3620288,Renal salbutamol clearance,"Renal salbutamol clearance (208; s.d. 51 ml min-1), however, was significantly less than that in the control group (283; s.d. 51 ml min-1).",Pharmacokinetics and metabolism of salbutamol in premature labour. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620288/),[ml] / [min],208,179722,DB01001,Salbutamol
,3620288,Renal salbutamol clearance,"Renal salbutamol clearance (208; s.d. 51 ml min-1), however, was significantly less than that in the control group (283; s.d. 51 ml min-1).",Pharmacokinetics and metabolism of salbutamol in premature labour. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620288/),[ml] / [min],283,179723,DB01001,Salbutamol
,19302910,FP,"The only notable differences were mean FP for particle sizes 2.3 to 3.2 microm (21.4 microg/dose for RPID, 25.6 microg/dose for Diskus) and for sizes 4.0 to 6.2 microm (17.3 microg/dose for RPID, 11.7 microg/dose for Diskus).","Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302910/),,17,181554,DB01001,Salbutamol
,19302910,maximum heart rate,"A small but statistically significant increase in maximum heart rate (5 beats/min) was noted in the RPID group (ratio, 1.05 [95% CI, 1.01 to 1.10]; P = 0.029).","Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302910/),[beats] / [min],5,181555,DB01001,Salbutamol
,11794808,fluxes,"The in vitro fluxes of theophylline and salbutamol sulfate from the formulation were 1.22 +/- 0.4 mg/h/cm2 and 13.36 +/- 1.02 microg/h/cm2, respectively.",Formulation and evaluation of controlled-release transdermal patches of theophylline-salbutamol sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11794808/),[mg] / [cm2·h],1.22,182807,DB01001,Salbutamol
,11794808,fluxes,"The in vitro fluxes of theophylline and salbutamol sulfate from the formulation were 1.22 +/- 0.4 mg/h/cm2 and 13.36 +/- 1.02 microg/h/cm2, respectively.",Formulation and evaluation of controlled-release transdermal patches of theophylline-salbutamol sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11794808/),[μg] / [cm2·h],13.36,182808,DB01001,Salbutamol
,11794808,Tmax,"The Tmax of the drugs was 3 h, and appreciable concentrations of the drugs above their MEC could be analyzed even after 12 h.",Formulation and evaluation of controlled-release transdermal patches of theophylline-salbutamol sulfate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11794808/),h,3,182809,DB01001,Salbutamol
,21983198,flow rate,"Chromatographic separation was achieved on a Shiseido Capcell Pak CR column (SCX:C(18)=1:4, 150 mm × 2.0 mm, 5 μm) with a mobile phase consisting of methanol/water (85:15, v/v) containing 20 mmol/L ammonium formate and 0.1% formic acid at a flow rate of 0.3 mL/min.",Simultaneous determination of ipratropium and salbutamol in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21983198/),[ml] / [min],0.3,184580,DB01001,Salbutamol
,11868799,urinary excretion amounts,"The mean (+/- SD) 30-min urinary excretion amounts of salbutamol for MDI, MDI+SP and NEB were 12.6+/-3.5, 27.1+/-6.0 and 16.1+/-4.6 microg, respectively.",Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868799/),μg,12.6,186090,DB01001,Salbutamol
,11868799,urinary excretion amounts,"The mean (+/- SD) 30-min urinary excretion amounts of salbutamol for MDI, MDI+SP and NEB were 12.6+/-3.5, 27.1+/-6.0 and 16.1+/-4.6 microg, respectively.",Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868799/),μg,27.1,186091,DB01001,Salbutamol
,11868799,urinary excretion amounts,"The mean (+/- SD) 30-min urinary excretion amounts of salbutamol for MDI, MDI+SP and NEB were 12.6+/-3.5, 27.1+/-6.0 and 16.1+/-4.6 microg, respectively.",Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868799/),μg,16.1,186092,DB01001,Salbutamol
,11868799,24-h,"The mean (+/-SD) 24-h urinary excretion values for salbutamol and its metabolite were 287.0+/-46.5, 198.1+/-34.7 and 253.4+/-138.3 microg, respectively.",Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868799/),μg,287.0,186093,DB01001,Salbutamol
,11868799,urinary excretion,"The mean (+/-SD) 24-h urinary excretion values for salbutamol and its metabolite were 287.0+/-46.5, 198.1+/-34.7 and 253.4+/-138.3 microg, respectively.",Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868799/),μg,287.0,186094,DB01001,Salbutamol
,11868799,urinary excretion,"The mean (+/-SD) 24-h urinary excretion values for salbutamol and its metabolite were 287.0+/-46.5, 198.1+/-34.7 and 253.4+/-138.3 microg, respectively.",Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868799/),μg,198.1,186095,DB01001,Salbutamol
,11868799,urinary excretion,"The mean (+/-SD) 24-h urinary excretion values for salbutamol and its metabolite were 287.0+/-46.5, 198.1+/-34.7 and 253.4+/-138.3 microg, respectively.",Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868799/),μg,253.4,186096,DB01001,Salbutamol
,11868799,emitted dose,The mean emitted dose from the MDI was 88.4+/-6.1 microg per actuation.,Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868799/),μg,88.4,186097,DB01001,Salbutamol
,31364911,AUC(0-t),"Estimated AUC(0-t) and Cmax ratios for salmeterol were, respectively, 1.08 (1.04-1.11) and 1.00 (0.94-1.04) for 100/50 μg FP/S, 1.03 (0.99-1.07) and 0.93 (0.87-1.00) for 250/50 μg, and 1.00 (0.96-1.04) and 0.86 (0.81-0.91) for 500/50 μg.",Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364911/),,1,186310,DB01001,Salbutamol
,31364911,AUC(0-t),"Estimated AUC(0-t) and Cmax ratios for salmeterol were, respectively, 1.08 (1.04-1.11) and 1.00 (0.94-1.04) for 100/50 μg FP/S, 1.03 (0.99-1.07) and 0.93 (0.87-1.00) for 250/50 μg, and 1.00 (0.96-1.04) and 0.86 (0.81-0.91) for 500/50 μg.",Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364911/),,0,186311,DB01001,Salbutamol
,31364911,Cmax ratios,"Estimated AUC(0-t) and Cmax ratios for salmeterol were, respectively, 1.08 (1.04-1.11) and 1.00 (0.94-1.04) for 100/50 μg FP/S, 1.03 (0.99-1.07) and 0.93 (0.87-1.00) for 250/50 μg, and 1.00 (0.96-1.04) and 0.86 (0.81-0.91) for 500/50 μg.",Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364911/),,1,186312,DB01001,Salbutamol
,20150524,first-order rate constant,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[1] / [h],4.07,187808,DB01001,Salbutamol
,20150524,relative clearance,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],890,187809,DB01001,Salbutamol
,20150524,volume of distribution,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),l,9800,187810,DB01001,Salbutamol
,20150524,first-order absorption rate constant,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[1] / [h],2.63,187811,DB01001,Salbutamol
,20150524,clearance,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],202,187812,DB01001,Salbutamol
,20150524,clearance,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],271,187813,DB01001,Salbutamol
,20150524,volume of distribution,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),l,947,187814,DB01001,Salbutamol
,20150524,maximum cortisol release rate,"Gender was a significant covariate on the maximum cortisol release rate (male, 3440 µg/h; female, 4310 µg/h).",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[μg] / [h],3440,187815,DB01001,Salbutamol
,20150524,maximum cortisol release rate,"Gender was a significant covariate on the maximum cortisol release rate (male, 3440 µg/h; female, 4310 µg/h).",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[μg] / [h],4310,187816,DB01001,Salbutamol
,6739311,terminal half-life,"Limited pharmacokinetic data suggest a long distribution phase, a terminal half-life of 3-8 hours, and 10-20% oral bioavailability.","Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6739311/),h,3-8,189827,DB01001,Salbutamol
,6739311,oral bioavailability,"Limited pharmacokinetic data suggest a long distribution phase, a terminal half-life of 3-8 hours, and 10-20% oral bioavailability.","Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6739311/),%,10-20,189828,DB01001,Salbutamol
,12207629,excretion,"Mean (s.d.) 30 min urinary salbutamol excretion after ORAL, MDI, NEB and NEBC was 0.4 (0.7), 12.1 (3.7), 15.0 (3.9) and 18.2 (5.7) microg, respectively (all P<0.001 compared with ORAL).",Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207629/),μg,0.4,193600,DB01001,Salbutamol
,12207629,excretion,"Mean (s.d.) 30 min urinary salbutamol excretion after ORAL, MDI, NEB and NEBC was 0.4 (0.7), 12.1 (3.7), 15.0 (3.9) and 18.2 (5.7) microg, respectively (all P<0.001 compared with ORAL).",Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207629/),μg,12.1,193601,DB01001,Salbutamol
,12207629,excretion,"Mean (s.d.) 30 min urinary salbutamol excretion after ORAL, MDI, NEB and NEBC was 0.4 (0.7), 12.1 (3.7), 15.0 (3.9) and 18.2 (5.7) microg, respectively (all P<0.001 compared with ORAL).",Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207629/),μg,15.0,193602,DB01001,Salbutamol
,12207629,excretion,"Mean (s.d.) 30 min urinary salbutamol excretion after ORAL, MDI, NEB and NEBC was 0.4 (0.7), 12.1 (3.7), 15.0 (3.9) and 18.2 (5.7) microg, respectively (all P<0.001 compared with ORAL).",Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207629/),μg,18.2,193603,DB01001,Salbutamol
,12207629,excretion,"The mean (s.d.) excretion of salbutamol plus its metabolite over 24 h post ORAL, MDI, NEB and NEBC dosing was 297.9 (38.3), 290.3 (41.4), 266.5 (44.6) and 151.7 (40.9) microg, respectively.",Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207629/),μg,297.9,193604,DB01001,Salbutamol
,12207629,excretion,"The mean (s.d.) excretion of salbutamol plus its metabolite over 24 h post ORAL, MDI, NEB and NEBC dosing was 297.9 (38.3), 290.3 (41.4), 266.5 (44.6) and 151.7 (40.9) microg, respectively.",Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207629/),μg,290.3,193605,DB01001,Salbutamol
,12207629,excretion,"The mean (s.d.) excretion of salbutamol plus its metabolite over 24 h post ORAL, MDI, NEB and NEBC dosing was 297.9 (38.3), 290.3 (41.4), 266.5 (44.6) and 151.7 (40.9) microg, respectively.",Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207629/),μg,266.5,193606,DB01001,Salbutamol
,12207629,excretion,"The mean (s.d.) excretion of salbutamol plus its metabolite over 24 h post ORAL, MDI, NEB and NEBC dosing was 297.9 (38.3), 290.3 (41.4), 266.5 (44.6) and 151.7 (40.9) microg, respectively.",Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207629/),μg,151.7,193607,DB01001,Salbutamol
,18969756,detection limit,The detection limit (signal-to-noise ratio = 3) was 1ngml(-1) salbutamol.,A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969756/),1/[ngml],3,196354,DB01001,Salbutamol
,18969756,detection limit,The detection limit (signal-to-noise ratio = 3) was 1ngml(-1) salbutamol.,A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969756/),1/[ngml],1,196355,DB01001,Salbutamol
,18969756,signal-to-noise ratio,The detection limit (signal-to-noise ratio = 3) was 1ngml(-1) salbutamol.,A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969756/),1/[ngml],3,196356,DB01001,Salbutamol
,18969756,signal-to-noise ratio,The detection limit (signal-to-noise ratio = 3) was 1ngml(-1) salbutamol.,A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969756/),1/[ngml],1,196357,DB01001,Salbutamol
,1516404,clearance,"Theophylline clearance was significantly higher when given with oral albuterol, in comparison with control (0.83 +/- 0.05 vs 0.73 +/- 0.06 ml/kg/min, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),[ml] / [kg·min],0.83,200056,DB01001,Salbutamol
,1516404,clearance,"Theophylline clearance was significantly higher when given with oral albuterol, in comparison with control (0.83 +/- 0.05 vs 0.73 +/- 0.06 ml/kg/min, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),[ml] / [kg·min],0.73,200057,DB01001,Salbutamol
,1516404,elimination t 1/2,"Theophylline elimination t 1/2 was shorter with the coadministration of oral albuterol, compared with control (7.1 +/- 0.3 vs. 8.1 +/- 0.6 h, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),h,7.1,200058,DB01001,Salbutamol
,1516404,elimination t 1/2,"Theophylline elimination t 1/2 was shorter with the coadministration of oral albuterol, compared with control (7.1 +/- 0.3 vs. 8.1 +/- 0.6 h, p less than 0.02).",Enhancement of theophylline clearance by oral albuterol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516404/),h,8.1,200059,DB01001,Salbutamol
,3768084,Maximum salbutamol plasma concentrations,"Maximum salbutamol plasma concentrations after intake of product A and product B on an empty stomach were reached after 2.3 +/- 0.9 (= mean +/- S.D.) and 2.4 +/- 1.1 h, respectively, and accounted for 14.3 +/- 2.5 and 12.8 +/- 2.6 micrograms X l-1, respectively.",Single dose absorption profiles and bioavailability of two different salbutamol tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768084/),[μg] / [l],14.3,201991,DB01001,Salbutamol
,3768084,Maximum salbutamol plasma concentrations,"Maximum salbutamol plasma concentrations after intake of product A and product B on an empty stomach were reached after 2.3 +/- 0.9 (= mean +/- S.D.) and 2.4 +/- 1.1 h, respectively, and accounted for 14.3 +/- 2.5 and 12.8 +/- 2.6 micrograms X l-1, respectively.",Single dose absorption profiles and bioavailability of two different salbutamol tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768084/),[μg] / [l],12.8,201992,DB01001,Salbutamol
,3768084,areas under the plasma concentration-time curves (AUC0----16),"The areas under the plasma concentration-time curves (AUC0----16), as obtained after administration of tablet A and tablet B, accounted for 73.5 +/- 14.0 and 65.0 +/- 11.8 micrograms X l-1 X h, respectively, the difference being marginally significant (p = 0.05).",Single dose absorption profiles and bioavailability of two different salbutamol tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768084/),[h·μg] / [l],73.5,201993,DB01001,Salbutamol
,3768084,areas under the plasma concentration-time curves (AUC0----16),"The areas under the plasma concentration-time curves (AUC0----16), as obtained after administration of tablet A and tablet B, accounted for 73.5 +/- 14.0 and 65.0 +/- 11.8 micrograms X l-1 X h, respectively, the difference being marginally significant (p = 0.05).",Single dose absorption profiles and bioavailability of two different salbutamol tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768084/),[h·μg] / [l],65.0,201994,DB01001,Salbutamol
,3768084,relative bioavailability,This results in a relative bioavailability of 114.3 +/- 15.7% for the product A 4-mg tablets.,Single dose absorption profiles and bioavailability of two different salbutamol tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768084/),%,114.3,201995,DB01001,Salbutamol
,22574510,AUC,"The exact values of AUC for four consecutive doses of Ventolin oral tablets were 150.58, 157.81, 164.41 and 162.78 ngxh/mL while the closest approximated AUC values were 149.24, 157.33, 164.25 and 162.28 ngxh/mL, respectively, as found by extended rectangular rule.",Application of the piecewise rational quadratic interpolant to the AUC calculation in the bioavailability study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22574510/),[h·ng] / [ml],150.58,202490,DB01001,Salbutamol
,22574510,AUC,"The exact values of AUC for four consecutive doses of Ventolin oral tablets were 150.58, 157.81, 164.41 and 162.78 ngxh/mL while the closest approximated AUC values were 149.24, 157.33, 164.25 and 162.28 ngxh/mL, respectively, as found by extended rectangular rule.",Application of the piecewise rational quadratic interpolant to the AUC calculation in the bioavailability study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22574510/),[h·ng] / [ml],157.81,202491,DB01001,Salbutamol
,22574510,AUC,"The exact values of AUC for four consecutive doses of Ventolin oral tablets were 150.58, 157.81, 164.41 and 162.78 ngxh/mL while the closest approximated AUC values were 149.24, 157.33, 164.25 and 162.28 ngxh/mL, respectively, as found by extended rectangular rule.",Application of the piecewise rational quadratic interpolant to the AUC calculation in the bioavailability study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22574510/),[h·ng] / [ml],164.41,202492,DB01001,Salbutamol
,22574510,AUC,"The exact values of AUC for four consecutive doses of Ventolin oral tablets were 150.58, 157.81, 164.41 and 162.78 ngxh/mL while the closest approximated AUC values were 149.24, 157.33, 164.25 and 162.28 ngxh/mL, respectively, as found by extended rectangular rule.",Application of the piecewise rational quadratic interpolant to the AUC calculation in the bioavailability study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22574510/),[h·ng] / [ml],162.78,202493,DB01001,Salbutamol
,22574510,AUC,"The exact values of AUC for four consecutive doses of Ventolin oral tablets were 150.58, 157.81, 164.41 and 162.78 ngxh/mL while the closest approximated AUC values were 149.24, 157.33, 164.25 and 162.28 ngxh/mL, respectively, as found by extended rectangular rule.",Application of the piecewise rational quadratic interpolant to the AUC calculation in the bioavailability study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22574510/),[h·ng] / [ml],149.24,202494,DB01001,Salbutamol
,22574510,AUC,"The exact values of AUC for four consecutive doses of Ventolin oral tablets were 150.58, 157.81, 164.41 and 162.78 ngxh/mL while the closest approximated AUC values were 149.24, 157.33, 164.25 and 162.28 ngxh/mL, respectively, as found by extended rectangular rule.",Application of the piecewise rational quadratic interpolant to the AUC calculation in the bioavailability study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22574510/),[h·ng] / [ml],157.33,202495,DB01001,Salbutamol
,22574510,AUC,"The exact values of AUC for four consecutive doses of Ventolin oral tablets were 150.58, 157.81, 164.41 and 162.78 ngxh/mL while the closest approximated AUC values were 149.24, 157.33, 164.25 and 162.28 ngxh/mL, respectively, as found by extended rectangular rule.",Application of the piecewise rational quadratic interpolant to the AUC calculation in the bioavailability study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22574510/),[h·ng] / [ml],164.25,202496,DB01001,Salbutamol
,22574510,AUC,"The exact values of AUC for four consecutive doses of Ventolin oral tablets were 150.58, 157.81, 164.41 and 162.78 ngxh/mL while the closest approximated AUC values were 149.24, 157.33, 164.25 and 162.28 ngxh/mL, respectively, as found by extended rectangular rule.",Application of the piecewise rational quadratic interpolant to the AUC calculation in the bioavailability study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22574510/),[h·ng] / [ml],162.28,202497,DB01001,Salbutamol
,11825095,peak concentration,"In patients who inhaled salmeterol 50microg twice daily for 10 months, a second peak concentration of 0.07 to 0.2 microg/L occurred 45 to 90 minutes after inhalation, probably because of the gastrointestinal absorption of the swallowed drug.",Clinical pharmacokinetics of salmeterol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825095/),[μg] / [l],0.07 to 0.2,203516,DB01001,Salbutamol
,11825095,elimination half-life,"The xinafoate moiety has no apparent pharmacological activity, is highly protein bound (>99%), largely to albumin, and has a long elimination half-life of about 12 to 15 days in healthy individuals.",Clinical pharmacokinetics of salmeterol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825095/),d,12 to 15,203517,DB01001,Salbutamol
,11825095,steady-state concentrations,"For this reason, it accumulates in plasma during repeated administration, with steady-state concentrations reaching about 80 to 90 microg/L in patients treated with salmeterol 50microg twice daily for several months.",Clinical pharmacokinetics of salmeterol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825095/),[μg] / [l],80 to 90,203518,DB01001,Salbutamol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,2.98,204217,DB01001,Salbutamol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,1.81,204218,DB01001,Salbutamol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,0.75,204219,DB01001,Salbutamol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,6.39,204220,DB01001,Salbutamol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,6.61,204221,DB01001,Salbutamol
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,4.28,204222,DB01001,Salbutamol
,7941494,peak plasma concentrations,"In the human subjects, statistically similar peak plasma concentrations of salbutamol were obtained (196 +/- 7 ng/ml for ventasol syrup and 185 +/- 6 ng/ml for ventolin syrup) 3 hours after oral administration of the formulations.",Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941494/),[ng] / [ml],196,209743,DB01001,Salbutamol
,7941494,peak plasma concentrations,"In the human subjects, statistically similar peak plasma concentrations of salbutamol were obtained (196 +/- 7 ng/ml for ventasol syrup and 185 +/- 6 ng/ml for ventolin syrup) 3 hours after oral administration of the formulations.",Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941494/),[ng] / [ml],185,209744,DB01001,Salbutamol
,7941494,ratio of the AUCo-infinity,"From the ratio of the AUCo-infinity for the formulations (1.04), a relative oral bioavailability of 104%, indicating equivalent total salbutamol output, was also obtained in the human subjects.",Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941494/),,1,209745,DB01001,Salbutamol
,7941494,relative oral bioavailability,"From the ratio of the AUCo-infinity for the formulations (1.04), a relative oral bioavailability of 104%, indicating equivalent total salbutamol output, was also obtained in the human subjects.",Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941494/),%,104,209746,DB01001,Salbutamol
,7941494,peak plasma concentrations,"Similarly, in the dogs, the formulations produced statistically equivalent peak plasma concentrations of salbutamol (259 +/- 24ng/ml for ventasol syrup and 285 +/- 29ng/ml for ventolin syrup) 3 hours after oral administration.",Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941494/),[ng] / [ml],259,209747,DB01001,Salbutamol
,7941494,peak plasma concentrations,"Similarly, in the dogs, the formulations produced statistically equivalent peak plasma concentrations of salbutamol (259 +/- 24ng/ml for ventasol syrup and 285 +/- 29ng/ml for ventolin syrup) 3 hours after oral administration.",Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941494/),[ng] / [ml],285,209748,DB01001,Salbutamol
,7941494,relative oral bioavailability,"Also, from the ratio of the AUCo-infinity for the formulations (1.02), a relative oral bioavailability of 102%, indicating similar total salbutamol output, was obtained in the dogs.",Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941494/),%,102,209749,DB01001,Salbutamol
,8254480,Fh,The Fh was about 10% and unchanged significantly with increasing i.p. dose (5-20 mg).,[Absorption and first-pass-effect of salbutamol after intraduodenal and intrarectal administration in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8254480/),%,10,216638,DB01001,Salbutamol
,8254480,bioavailability (EBA),"The results of the i.d. and i.r. dosing were as follows; for the extent of bioavailability (EBA), 7.7 +/- 1.5% and 14.5 +/- 2.3%, for the fraction of dose absorbed (fa), 93.9 +/- 3.7% and 33.8 +/- 3.3%, and for the fraction of absorbed SB which avoids first-pass-effects (F), 8.4 +/- 1.9% and 43.0 +/- 6.0% (mean +/- S. E., n = 4).",[Absorption and first-pass-effect of salbutamol after intraduodenal and intrarectal administration in rabbits]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8254480/),%,7.7,216639,DB01001,Salbutamol
,8254480,bioavailability (EBA),"The results of the i.d. and i.r. dosing were as follows; for the extent of bioavailability (EBA), 7.7 +/- 1.5% and 14.5 +/- 2.3%, for the fraction of dose absorbed (fa), 93.9 +/- 3.7% and 33.8 +/- 3.3%, and for the fraction of absorbed SB which avoids first-pass-effects (F), 8.4 +/- 1.9% and 43.0 +/- 6.0% (mean +/- S. E., n = 4).",[Absorption and first-pass-effect of salbutamol after intraduodenal and intrarectal administration in rabbits]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8254480/),%,14.5,216640,DB01001,Salbutamol
,8254480,fraction of dose absorbed (fa),"The results of the i.d. and i.r. dosing were as follows; for the extent of bioavailability (EBA), 7.7 +/- 1.5% and 14.5 +/- 2.3%, for the fraction of dose absorbed (fa), 93.9 +/- 3.7% and 33.8 +/- 3.3%, and for the fraction of absorbed SB which avoids first-pass-effects (F), 8.4 +/- 1.9% and 43.0 +/- 6.0% (mean +/- S. E., n = 4).",[Absorption and first-pass-effect of salbutamol after intraduodenal and intrarectal administration in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8254480/),%,93.9,216641,DB01001,Salbutamol
,8254480,fraction of dose absorbed (fa),"The results of the i.d. and i.r. dosing were as follows; for the extent of bioavailability (EBA), 7.7 +/- 1.5% and 14.5 +/- 2.3%, for the fraction of dose absorbed (fa), 93.9 +/- 3.7% and 33.8 +/- 3.3%, and for the fraction of absorbed SB which avoids first-pass-effects (F), 8.4 +/- 1.9% and 43.0 +/- 6.0% (mean +/- S. E., n = 4).",[Absorption and first-pass-effect of salbutamol after intraduodenal and intrarectal administration in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8254480/),%,33.8,216642,DB01001,Salbutamol
,8254480,fraction of absorbed,"The results of the i.d. and i.r. dosing were as follows; for the extent of bioavailability (EBA), 7.7 +/- 1.5% and 14.5 +/- 2.3%, for the fraction of dose absorbed (fa), 93.9 +/- 3.7% and 33.8 +/- 3.3%, and for the fraction of absorbed SB which avoids first-pass-effects (F), 8.4 +/- 1.9% and 43.0 +/- 6.0% (mean +/- S. E., n = 4).",[Absorption and first-pass-effect of salbutamol after intraduodenal and intrarectal administration in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8254480/),%,8.4,216643,DB01001,Salbutamol
,8254480,fraction of absorbed,"The results of the i.d. and i.r. dosing were as follows; for the extent of bioavailability (EBA), 7.7 +/- 1.5% and 14.5 +/- 2.3%, for the fraction of dose absorbed (fa), 93.9 +/- 3.7% and 33.8 +/- 3.3%, and for the fraction of absorbed SB which avoids first-pass-effects (F), 8.4 +/- 1.9% and 43.0 +/- 6.0% (mean +/- S. E., n = 4).",[Absorption and first-pass-effect of salbutamol after intraduodenal and intrarectal administration in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8254480/),%,43.0,216644,DB01001,Salbutamol
,8824691,clearance,"4 The following pharmacokinetic parameters for (+)S and (-)R salbutamol were found to be significantly different (P < 0.05) after intravenous administration (clearance 0.39 +/- 0.12 vs 0.62 +/- 0.18 1 h-1 kg-1, terminal phase half-life 2.85 +/- 0.83 vs 2.00 +/- 0.49 h, amount excreted unchanged in urine 55 +/- 11 vs 46 +/- 8%) and following oral administration (amount excreted unchanged in urine 32 +/- 11 vs 8 +/- 4% and bioavailability 0.71 +/- 0.09 vs 0.30 +/- 0.07).",Enantioselective disposition of salbutamol in man following oral and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824691/),[1] / [h·kg],0.39,216763,DB01001,Salbutamol
,8824691,clearance,"4 The following pharmacokinetic parameters for (+)S and (-)R salbutamol were found to be significantly different (P < 0.05) after intravenous administration (clearance 0.39 +/- 0.12 vs 0.62 +/- 0.18 1 h-1 kg-1, terminal phase half-life 2.85 +/- 0.83 vs 2.00 +/- 0.49 h, amount excreted unchanged in urine 55 +/- 11 vs 46 +/- 8%) and following oral administration (amount excreted unchanged in urine 32 +/- 11 vs 8 +/- 4% and bioavailability 0.71 +/- 0.09 vs 0.30 +/- 0.07).",Enantioselective disposition of salbutamol in man following oral and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824691/),[1] / [h·kg],0.62,216764,DB01001,Salbutamol
,8824691,terminal phase half-life,"4 The following pharmacokinetic parameters for (+)S and (-)R salbutamol were found to be significantly different (P < 0.05) after intravenous administration (clearance 0.39 +/- 0.12 vs 0.62 +/- 0.18 1 h-1 kg-1, terminal phase half-life 2.85 +/- 0.83 vs 2.00 +/- 0.49 h, amount excreted unchanged in urine 55 +/- 11 vs 46 +/- 8%) and following oral administration (amount excreted unchanged in urine 32 +/- 11 vs 8 +/- 4% and bioavailability 0.71 +/- 0.09 vs 0.30 +/- 0.07).",Enantioselective disposition of salbutamol in man following oral and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824691/),h,2.85,216765,DB01001,Salbutamol
,8824691,terminal phase half-life,"4 The following pharmacokinetic parameters for (+)S and (-)R salbutamol were found to be significantly different (P < 0.05) after intravenous administration (clearance 0.39 +/- 0.12 vs 0.62 +/- 0.18 1 h-1 kg-1, terminal phase half-life 2.85 +/- 0.83 vs 2.00 +/- 0.49 h, amount excreted unchanged in urine 55 +/- 11 vs 46 +/- 8%) and following oral administration (amount excreted unchanged in urine 32 +/- 11 vs 8 +/- 4% and bioavailability 0.71 +/- 0.09 vs 0.30 +/- 0.07).",Enantioselective disposition of salbutamol in man following oral and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824691/),h,2.00,216766,DB01001,Salbutamol
,8824691,amount excreted unchanged in urine,"4 The following pharmacokinetic parameters for (+)S and (-)R salbutamol were found to be significantly different (P < 0.05) after intravenous administration (clearance 0.39 +/- 0.12 vs 0.62 +/- 0.18 1 h-1 kg-1, terminal phase half-life 2.85 +/- 0.83 vs 2.00 +/- 0.49 h, amount excreted unchanged in urine 55 +/- 11 vs 46 +/- 8%) and following oral administration (amount excreted unchanged in urine 32 +/- 11 vs 8 +/- 4% and bioavailability 0.71 +/- 0.09 vs 0.30 +/- 0.07).",Enantioselective disposition of salbutamol in man following oral and intravenous administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824691/),%,55,216767,DB01001,Salbutamol
,8824691,amount excreted unchanged in urine,"4 The following pharmacokinetic parameters for (+)S and (-)R salbutamol were found to be significantly different (P < 0.05) after intravenous administration (clearance 0.39 +/- 0.12 vs 0.62 +/- 0.18 1 h-1 kg-1, terminal phase half-life 2.85 +/- 0.83 vs 2.00 +/- 0.49 h, amount excreted unchanged in urine 55 +/- 11 vs 46 +/- 8%) and following oral administration (amount excreted unchanged in urine 32 +/- 11 vs 8 +/- 4% and bioavailability 0.71 +/- 0.09 vs 0.30 +/- 0.07).",Enantioselective disposition of salbutamol in man following oral and intravenous administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824691/),%,46,216768,DB01001,Salbutamol
,8824691,amount excreted unchanged,"4 The following pharmacokinetic parameters for (+)S and (-)R salbutamol were found to be significantly different (P < 0.05) after intravenous administration (clearance 0.39 +/- 0.12 vs 0.62 +/- 0.18 1 h-1 kg-1, terminal phase half-life 2.85 +/- 0.83 vs 2.00 +/- 0.49 h, amount excreted unchanged in urine 55 +/- 11 vs 46 +/- 8%) and following oral administration (amount excreted unchanged in urine 32 +/- 11 vs 8 +/- 4% and bioavailability 0.71 +/- 0.09 vs 0.30 +/- 0.07).",Enantioselective disposition of salbutamol in man following oral and intravenous administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824691/),%,32,216769,DB01001,Salbutamol
,8824691,amount excreted unchanged,"4 The following pharmacokinetic parameters for (+)S and (-)R salbutamol were found to be significantly different (P < 0.05) after intravenous administration (clearance 0.39 +/- 0.12 vs 0.62 +/- 0.18 1 h-1 kg-1, terminal phase half-life 2.85 +/- 0.83 vs 2.00 +/- 0.49 h, amount excreted unchanged in urine 55 +/- 11 vs 46 +/- 8%) and following oral administration (amount excreted unchanged in urine 32 +/- 11 vs 8 +/- 4% and bioavailability 0.71 +/- 0.09 vs 0.30 +/- 0.07).",Enantioselective disposition of salbutamol in man following oral and intravenous administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824691/),%,8,216770,DB01001,Salbutamol
,8824691,bioavailability,"4 The following pharmacokinetic parameters for (+)S and (-)R salbutamol were found to be significantly different (P < 0.05) after intravenous administration (clearance 0.39 +/- 0.12 vs 0.62 +/- 0.18 1 h-1 kg-1, terminal phase half-life 2.85 +/- 0.83 vs 2.00 +/- 0.49 h, amount excreted unchanged in urine 55 +/- 11 vs 46 +/- 8%) and following oral administration (amount excreted unchanged in urine 32 +/- 11 vs 8 +/- 4% and bioavailability 0.71 +/- 0.09 vs 0.30 +/- 0.07).",Enantioselective disposition of salbutamol in man following oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824691/),,0.71,216771,DB01001,Salbutamol
,8824691,bioavailability,"4 The following pharmacokinetic parameters for (+)S and (-)R salbutamol were found to be significantly different (P < 0.05) after intravenous administration (clearance 0.39 +/- 0.12 vs 0.62 +/- 0.18 1 h-1 kg-1, terminal phase half-life 2.85 +/- 0.83 vs 2.00 +/- 0.49 h, amount excreted unchanged in urine 55 +/- 11 vs 46 +/- 8%) and following oral administration (amount excreted unchanged in urine 32 +/- 11 vs 8 +/- 4% and bioavailability 0.71 +/- 0.09 vs 0.30 +/- 0.07).",Enantioselective disposition of salbutamol in man following oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824691/),,0.30,216772,DB01001,Salbutamol
,3793958,elimination phase half-life,"The elimination phase half-life was determined to be 6.5 hours, which is similar to the values reported following single-dose administration.",Multiple-dose albuterol kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793958/),h,6.5,217564,DB01001,Salbutamol
,10508799,area under the curve (AUC),The area under the curve (AUC) of the plasma levels over time was significantly lower for the (S)- than for the (R)-enantiomer-395.5 +/- 141.0 (SE) versus 882.7 +/- 126.4 ng.,Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508799/),ng,395.5,224951,DB01001,Salbutamol
,10508799,area under the curve (AUC),The area under the curve (AUC) of the plasma levels over time was significantly lower for the (S)- than for the (R)-enantiomer-395.5 +/- 141.0 (SE) versus 882.7 +/- 126.4 ng.,Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508799/),ng,882.7,224952,DB01001,Salbutamol
>,10508799,R/S ratio,"The R/S ratio in urine at 0. 5 h after albuterol was > 1, reflecting the higher plasma level of the (R)-enantiomer.",Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508799/),,1,224953,DB01001,Salbutamol
,18378197,retention time,"The liquid chromatography was performed on a Hanbon Sci. & Tech. Lichrospher CN (150 mm x 4.6 mm, i.d., 5 microm) column (Hanbon, China) at 20 degrees C. A mixture of 0.03% acetic acid and methanol (50:50, v/v) was used as isocratic mobile phase to give the retention time 3.60 min for ritodrine and 2.94 min for salbutamol.",Determination of ritodrine in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18378197/),min,3.60,228059,DB01001,Salbutamol
,18378197,retention time,"The liquid chromatography was performed on a Hanbon Sci. & Tech. Lichrospher CN (150 mm x 4.6 mm, i.d., 5 microm) column (Hanbon, China) at 20 degrees C. A mixture of 0.03% acetic acid and methanol (50:50, v/v) was used as isocratic mobile phase to give the retention time 3.60 min for ritodrine and 2.94 min for salbutamol.",Determination of ritodrine in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18378197/),min,2.94,228060,DB01001,Salbutamol
,18378197,half-life,The half-life is 2.54+/-0.67 h.,Determination of ritodrine in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18378197/),h,2.54,228061,DB01001,Salbutamol
,2759134,absorption rate constant,"However, salbutamol pretreatment resulted in significant reduction in the absorption rate constant of SMZ from 1.168 +/- 0.509 h-1 (mean +/- S.D.) to 0.688 +/- 0.348 h-1 (P less than 0.025), and this was associated with prolongation of tmax from 3.00 +/- 1.69 h to 4.33 +/- 1.51 h (P less than 0.025).",Effects of salbutamol on the absorption and disposition of sulphamethoxazole in adult volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2759134/),1/[h],1.168,230384,DB01001,Salbutamol
,2759134,absorption rate constant,"However, salbutamol pretreatment resulted in significant reduction in the absorption rate constant of SMZ from 1.168 +/- 0.509 h-1 (mean +/- S.D.) to 0.688 +/- 0.348 h-1 (P less than 0.025), and this was associated with prolongation of tmax from 3.00 +/- 1.69 h to 4.33 +/- 1.51 h (P less than 0.025).",Effects of salbutamol on the absorption and disposition of sulphamethoxazole in adult volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2759134/),1/[h],0.688,230385,DB01001,Salbutamol
,2759134,tmax,"However, salbutamol pretreatment resulted in significant reduction in the absorption rate constant of SMZ from 1.168 +/- 0.509 h-1 (mean +/- S.D.) to 0.688 +/- 0.348 h-1 (P less than 0.025), and this was associated with prolongation of tmax from 3.00 +/- 1.69 h to 4.33 +/- 1.51 h (P less than 0.025).",Effects of salbutamol on the absorption and disposition of sulphamethoxazole in adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2759134/),h,3.00,230386,DB01001,Salbutamol
,2759134,tmax,"However, salbutamol pretreatment resulted in significant reduction in the absorption rate constant of SMZ from 1.168 +/- 0.509 h-1 (mean +/- S.D.) to 0.688 +/- 0.348 h-1 (P less than 0.025), and this was associated with prolongation of tmax from 3.00 +/- 1.69 h to 4.33 +/- 1.51 h (P less than 0.025).",Effects of salbutamol on the absorption and disposition of sulphamethoxazole in adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2759134/),h,4.33,230387,DB01001,Salbutamol
,19927035,urinary concentrations (Cmax),"We found differences in median urinary concentrations (Cmax) of 260.9 and 2422.2 ng x mL(-1), respectively (P < 0.005).",Blood and urinary concentrations of salbutamol in asthmatic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927035/),[ng] / [ml],260.9,232323,DB01001,Salbutamol
,19927035,urinary concentrations (Cmax),"We found differences in median urinary concentrations (Cmax) of 260.9 and 2422.2 ng x mL(-1), respectively (P < 0.005).",Blood and urinary concentrations of salbutamol in asthmatic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927035/),[ng] / [ml],2422.2,232324,DB01001,Salbutamol
,19927035,Cmax,"A difference in median Cmax after inhalation and oral treatment was found: 1.75 and 18.77 ng x mL(-1), respectively (P < 0.05).",Blood and urinary concentrations of salbutamol in asthmatic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927035/),[ng] / [ml],1.75,232325,DB01001,Salbutamol
,19927035,Cmax,"A difference in median Cmax after inhalation and oral treatment was found: 1.75 and 18.77 ng x mL(-1), respectively (P < 0.05).",Blood and urinary concentrations of salbutamol in asthmatic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927035/),[ng] / [ml],18.77,232326,DB01001,Salbutamol
,3989697,areas under the plasma concentration-time curves,The areas under the plasma concentration-time curves were 68-78 h X ng/mL.,Comparative bioavailability and pharmacokinetics of three formulations of albuterol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3989697/),[h·ng] / [ml],68-78,232658,DB01001,Salbutamol
,3989697,elimination phase half-live (t1/2 beta),The drug elimination phase half-live (t1/2 beta) ranged from 4.8 to 5.5 h.,Comparative bioavailability and pharmacokinetics of three formulations of albuterol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3989697/),h,4.8 to 5.5,232659,DB01001,Salbutamol
,11745909,peak plasma concentrations,"The mean peak plasma concentrations were 6.3, 10.9 and 30.5 ng ml(-1) at the three doses, respectively, and occurred at 30, 52.5 and 30 min (median t(max)).",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),[ng] / [ml],6.3,233018,DB01001,Salbutamol
,11745909,peak plasma concentrations,"The mean peak plasma concentrations were 6.3, 10.9 and 30.5 ng ml(-1) at the three doses, respectively, and occurred at 30, 52.5 and 30 min (median t(max)).",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),[ng] / [ml],10.9,233019,DB01001,Salbutamol
,11745909,peak plasma concentrations,"The mean peak plasma concentrations were 6.3, 10.9 and 30.5 ng ml(-1) at the three doses, respectively, and occurred at 30, 52.5 and 30 min (median t(max)).",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),[ng] / [ml],30.5,233020,DB01001,Salbutamol
,11745909,peak plasma concentrations,"The mean peak plasma concentrations were 6.3, 10.9 and 30.5 ng ml(-1) at the three doses, respectively, and occurred at 30, 52.5 and 30 min (median t(max)).",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),min,30,233021,DB01001,Salbutamol
,11745909,peak plasma concentrations,"The mean peak plasma concentrations were 6.3, 10.9 and 30.5 ng ml(-1) at the three doses, respectively, and occurred at 30, 52.5 and 30 min (median t(max)).",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),min,52.5,233022,DB01001,Salbutamol
,11745909,t(max),"The mean peak plasma concentrations were 6.3, 10.9 and 30.5 ng ml(-1) at the three doses, respectively, and occurred at 30, 52.5 and 30 min (median t(max)).",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),min,30,233023,DB01001,Salbutamol
,11745909,t(max),"The mean peak plasma concentrations were 6.3, 10.9 and 30.5 ng ml(-1) at the three doses, respectively, and occurred at 30, 52.5 and 30 min (median t(max)).",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),min,52.5,233024,DB01001,Salbutamol
,11745909,AUC(t),"The mean AUC(t) values were 1852, 2889 and 7677 ng min ml(-1).",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),[min·ng] / [ml],1852,233025,DB01001,Salbutamol
,11745909,AUC(t),"The mean AUC(t) values were 1852, 2889 and 7677 ng min ml(-1).",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),[min·ng] / [ml],2889,233026,DB01001,Salbutamol
,11745909,AUC(t),"The mean AUC(t) values were 1852, 2889 and 7677 ng min ml(-1).",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),[min·ng] / [ml],7677,233027,DB01001,Salbutamol
,11745909,apparent plasma clearance (CL/F),"The apparent plasma clearance (CL/F) and volume of distribution (V(z)/F) were, respectively, 1168 ml min(-1) and 430 l at the dose of 2 mg, 1143 ml min(-1) and 468 l at the dose of 4 mg, and 1141 ml min(-1) and 486 l at the dose of 8 mg.",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),[ml] / [min],1168,233028,DB01001,Salbutamol
,11745909,apparent plasma clearance (CL/F),"The apparent plasma clearance (CL/F) and volume of distribution (V(z)/F) were, respectively, 1168 ml min(-1) and 430 l at the dose of 2 mg, 1143 ml min(-1) and 468 l at the dose of 4 mg, and 1141 ml min(-1) and 486 l at the dose of 8 mg.",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),[ml] / [min],1143,233029,DB01001,Salbutamol
,11745909,apparent plasma clearance (CL/F),"The apparent plasma clearance (CL/F) and volume of distribution (V(z)/F) were, respectively, 1168 ml min(-1) and 430 l at the dose of 2 mg, 1143 ml min(-1) and 468 l at the dose of 4 mg, and 1141 ml min(-1) and 486 l at the dose of 8 mg.",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),[ml] / [min],1141,233030,DB01001,Salbutamol
,11745909,volume of distribution (V(z)/F),"The apparent plasma clearance (CL/F) and volume of distribution (V(z)/F) were, respectively, 1168 ml min(-1) and 430 l at the dose of 2 mg, 1143 ml min(-1) and 468 l at the dose of 4 mg, and 1141 ml min(-1) and 486 l at the dose of 8 mg.",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),l,430,233031,DB01001,Salbutamol
,11745909,volume of distribution (V(z)/F),"The apparent plasma clearance (CL/F) and volume of distribution (V(z)/F) were, respectively, 1168 ml min(-1) and 430 l at the dose of 2 mg, 1143 ml min(-1) and 468 l at the dose of 4 mg, and 1141 ml min(-1) and 486 l at the dose of 8 mg.",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),[ml] / [min],1141,233032,DB01001,Salbutamol
,11745909,volume of distribution (V(z)/F),"The apparent plasma clearance (CL/F) and volume of distribution (V(z)/F) were, respectively, 1168 ml min(-1) and 430 l at the dose of 2 mg, 1143 ml min(-1) and 468 l at the dose of 4 mg, and 1141 ml min(-1) and 486 l at the dose of 8 mg.",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),l,486,233033,DB01001,Salbutamol
,11745909,apparent elimination half-life,"The apparent elimination half-life averaged 4.5, 5.0 and 4.6 h at the three doses, respectively.",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),h,4.5,233034,DB01001,Salbutamol
,11745909,apparent elimination half-life,"The apparent elimination half-life averaged 4.5, 5.0 and 4.6 h at the three doses, respectively.",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),h,5.0,233035,DB01001,Salbutamol
,11745909,apparent elimination half-life,"The apparent elimination half-life averaged 4.5, 5.0 and 4.6 h at the three doses, respectively.",Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745909/),h,4.6,233036,DB01001,Salbutamol
,8492296,bioavailability,"The bioavailability estimated by the area under the blood concentration-time curve (AUC) of SB from 0 to 9 h after oral and rectal administrations were 1.1 +/- 0.5% and 7.8 +/- 2.2% (mean +/- S. E., n = 5), respectively.",[Comparison of bioavailability of salbutamol between oral and rectal administration in rabbits]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8492296/),%,1.1,234745,DB01001,Salbutamol
,8492296,bioavailability,"The bioavailability estimated by the area under the blood concentration-time curve (AUC) of SB from 0 to 9 h after oral and rectal administrations were 1.1 +/- 0.5% and 7.8 +/- 2.2% (mean +/- S. E., n = 5), respectively.",[Comparison of bioavailability of salbutamol between oral and rectal administration in rabbits]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8492296/),%,7.8,234746,DB01001,Salbutamol
,8492296,Percent of dose excreted in urine,"Percent of dose excreted in urine as total SB (SB+SBG) 10 h after oral and rectal administrations were 77.3 +/- 3.82% and 9.80 +/- 0.15% (mean +/- S. E., n = 3), respectively, which indicating relatively good oral and poor rectal SB absorption.",[Comparison of bioavailability of salbutamol between oral and rectal administration in rabbits]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8492296/),%,77.3,234747,DB01001,Salbutamol
,8492296,Percent of dose excreted in urine,"Percent of dose excreted in urine as total SB (SB+SBG) 10 h after oral and rectal administrations were 77.3 +/- 3.82% and 9.80 +/- 0.15% (mean +/- S. E., n = 3), respectively, which indicating relatively good oral and poor rectal SB absorption.",[Comparison of bioavailability of salbutamol between oral and rectal administration in rabbits]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8492296/),%,9.80,234748,DB01001,Salbutamol
,8087354,Maximum serum concentrations,Maximum serum concentrations of salbutamol were 4.4 +/- 1.8 ng/ml after 1 puff and 419 +/- 168 ng/ml after 20 puffs.,Proximate delivery of a large experimental dose from salbutamol MDI induces epithelial airway lesions in intubated rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087354/),[ng] / [ml],4.4,235316,DB01001,Salbutamol
,8087354,Maximum serum concentrations,Maximum serum concentrations of salbutamol were 4.4 +/- 1.8 ng/ml after 1 puff and 419 +/- 168 ng/ml after 20 puffs.,Proximate delivery of a large experimental dose from salbutamol MDI induces epithelial airway lesions in intubated rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087354/),[ng] / [ml],419,235317,DB01001,Salbutamol
,8087354,total body clearance,"After 20 puffs, the total body clearance of salbutamol was 108 +/- 27 ml/min/kg, volume of distribution was 3.6 +/- 1.8 L/kg, and the elimination half-life was 22 +/- 7 min.",Proximate delivery of a large experimental dose from salbutamol MDI induces epithelial airway lesions in intubated rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087354/),[ml] / [kg·min],108,235318,DB01001,Salbutamol
,8087354,volume of distribution,"After 20 puffs, the total body clearance of salbutamol was 108 +/- 27 ml/min/kg, volume of distribution was 3.6 +/- 1.8 L/kg, and the elimination half-life was 22 +/- 7 min.",Proximate delivery of a large experimental dose from salbutamol MDI induces epithelial airway lesions in intubated rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087354/),[l] / [kg],3.6,235319,DB01001,Salbutamol
,8087354,elimination half-life,"After 20 puffs, the total body clearance of salbutamol was 108 +/- 27 ml/min/kg, volume of distribution was 3.6 +/- 1.8 L/kg, and the elimination half-life was 22 +/- 7 min.",Proximate delivery of a large experimental dose from salbutamol MDI induces epithelial airway lesions in intubated rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087354/),min,22,235320,DB01001,Salbutamol
,2687008,Cmax,"At steady-state the geometric mean values for Cmax were 8.2 ng/ml for 4 mg, and 16.1 ng/ml for 8 mg.",Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687008/),[ng] / [ml],8.2,241598,DB01001,Salbutamol
,2687008,Cmax,"At steady-state the geometric mean values for Cmax were 8.2 ng/ml for 4 mg, and 16.1 ng/ml for 8 mg.",Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687008/),[ng] / [ml],16.1,241599,DB01001,Salbutamol
,2687008,tmax,Median tmax values were 300 and 240 min respectively.,Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687008/),min,300,241600,DB01001,Salbutamol
,2687008,tmax,Median tmax values were 300 and 240 min respectively.,Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687008/),min,240,241601,DB01001,Salbutamol
,2687008,AUC (0-12),The geometric mean AUC (0-12) were 4507 ng.min.,Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687008/),min·ng,4507,241602,DB01001,Salbutamol
,2687008,Peak to trough fluctuation ratios,Peak to trough fluctuation ratios were 0.577 and 0.572.,Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687008/),,0.577,241603,DB01001,Salbutamol
,2687008,Peak to trough fluctuation ratios,Peak to trough fluctuation ratios were 0.577 and 0.572.,Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687008/),,0.572,241604,DB01001,Salbutamol
,25988297,LOD,"The LOD was 0.3 ng/g, and the LOQ was 1 ng/g.",Validation of a confirmatory method of salbutamol in sheep hair by UPLC-MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25988297/),[ng] / [g],0.3,243930,DB01001,Salbutamol
,25988297,LOQ,"The LOD was 0.3 ng/g, and the LOQ was 1 ng/g.",Validation of a confirmatory method of salbutamol in sheep hair by UPLC-MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25988297/),[ng] / [g],1,243931,DB01001,Salbutamol
,25988297,Recoveries,"Recoveries were 89-106%, and coefficients of variation were 3.2-13.9%.",Validation of a confirmatory method of salbutamol in sheep hair by UPLC-MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25988297/),%,89-106,243932,DB01001,Salbutamol
,10984366,peak ex,"A randomized, single-blind, placebo-controlled study was performed in 74 patients between 18 and 55 years old presenting to the emergency department (ED) for treatment of acute asthma with a peak expiratory flow (PEF) of 50% or less than the normal predicted value.",Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984366/),%,50,246128,DB01001,Salbutamol
,16179215,FE,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,167,246316,DB01001,Salbutamol
,16179215,FE,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,130,246317,DB01001,Salbutamol
,16179215,peak FEV1,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,262,246318,DB01001,Salbutamol
,16179215,peak FEV1,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,216,246319,DB01001,Salbutamol
,1457264,relative bioavailability,2. Total urinary recovery of salbutamol and its sulphate conjugate indicated a mean (s.d.) relative bioavailability of 92.2 (24.8) % following inhalation compared with oral administration.,Determination of the relative bioavailability of salbutamol to the lung following inhalation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1457264/),%,92.2,247969,DB01001,Salbutamol
,1457264,elimination half-lives,"3. The mean (s.d.) elimination half-lives of salbutamol and its sulphate conjugate were 5.7 (1.4) and 4.1 (2.1) h, respectively, after oral administration and following inhalation they were 6.1 (2.1) and 5.1 (1.0) h, respectively.",Determination of the relative bioavailability of salbutamol to the lung following inhalation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1457264/),h,5.7,247970,DB01001,Salbutamol
,1457264,elimination half-lives,"3. The mean (s.d.) elimination half-lives of salbutamol and its sulphate conjugate were 5.7 (1.4) and 4.1 (2.1) h, respectively, after oral administration and following inhalation they were 6.1 (2.1) and 5.1 (1.0) h, respectively.",Determination of the relative bioavailability of salbutamol to the lung following inhalation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1457264/),h,4.1,247971,DB01001,Salbutamol
,1457264,elimination half-lives,"3. The mean (s.d.) elimination half-lives of salbutamol and its sulphate conjugate were 5.7 (1.4) and 4.1 (2.1) h, respectively, after oral administration and following inhalation they were 6.1 (2.1) and 5.1 (1.0) h, respectively.",Determination of the relative bioavailability of salbutamol to the lung following inhalation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1457264/),h,6.1,247972,DB01001,Salbutamol
,1457264,elimination half-lives,"3. The mean (s.d.) elimination half-lives of salbutamol and its sulphate conjugate were 5.7 (1.4) and 4.1 (2.1) h, respectively, after oral administration and following inhalation they were 6.1 (2.1) and 5.1 (1.0) h, respectively.",Determination of the relative bioavailability of salbutamol to the lung following inhalation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1457264/),h,5.1,247973,DB01001,Salbutamol
,2598971,terminal half-life,"The mean terminal half-life was 256 min, similar to previously reported values in healthy adults.",Pharmacokinetics of intravenous salbutamol in renal insufficiency and its biological effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598971/),min,256,249959,DB01001,Salbutamol
,2598971,clearance,The mean clearance (167 ml/min) and the mean volume of distribution (551) were decreased.,Pharmacokinetics of intravenous salbutamol in renal insufficiency and its biological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598971/),[ml] / [min],167,249960,DB01001,Salbutamol
,2598971,volume of distribution,The mean clearance (167 ml/min) and the mean volume of distribution (551) were decreased.,Pharmacokinetics of intravenous salbutamol in renal insufficiency and its biological effects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598971/),,551,249961,DB01001,Salbutamol
,1880222,Cmax,The mean Cmax for Volmax; administered after a meal was 19% lower than that of the drug administered in a fasting state (3.9 ng/mL vs. 4.8 ng/mL; P less than .01).,Albuterol extended-release products: effect of food on the pharmacokinetics of single oral doses of Volmax and Proventil Repetabs in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880222/),[ng] / [ml],3.9,252480,DB01001,Salbutamol
,1880222,Cmax,The mean Cmax for Volmax; administered after a meal was 19% lower than that of the drug administered in a fasting state (3.9 ng/mL vs. 4.8 ng/mL; P less than .01).,Albuterol extended-release products: effect of food on the pharmacokinetics of single oral doses of Volmax and Proventil Repetabs in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880222/),[ng] / [ml],4.8,252481,DB01001,Salbutamol
,1880222,Cmax,An almost equivalent lowering of the mean Cmax (by 21%) was observed for Proventil Repetabs after administration with a meal versus fasting (4.2 ng/mL vs. 5.3 ng/mL; P less than .01).,Albuterol extended-release products: effect of food on the pharmacokinetics of single oral doses of Volmax and Proventil Repetabs in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880222/),[ng] / [ml],4.2,252482,DB01001,Salbutamol
,1880222,Cmax,An almost equivalent lowering of the mean Cmax (by 21%) was observed for Proventil Repetabs after administration with a meal versus fasting (4.2 ng/mL vs. 5.3 ng/mL; P less than .01).,Albuterol extended-release products: effect of food on the pharmacokinetics of single oral doses of Volmax and Proventil Repetabs in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880222/),[ng] / [ml],5.3,252483,DB01001,Salbutamol
,1880222,tmax,The tmax occurred significantly later during the fed treatment for Volmax only (4.9 hours fasted vs. 6.4 hours fed; P less than .01).,Albuterol extended-release products: effect of food on the pharmacokinetics of single oral doses of Volmax and Proventil Repetabs in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880222/),h,4.9,252484,DB01001,Salbutamol
,1880222,tmax,The tmax occurred significantly later during the fed treatment for Volmax only (4.9 hours fasted vs. 6.4 hours fed; P less than .01).,Albuterol extended-release products: effect of food on the pharmacokinetics of single oral doses of Volmax and Proventil Repetabs in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880222/),h,6.4,252485,DB01001,Salbutamol
,31964790,minimum sputum concentration [C min],"The average minimum concentration of vancomycin in sputum remained above the usual MIC values for MRSA for up to 24 h (minimum sputum concentration [C min], 32-mg dose = 3.05 μg/ml, 80-mg dose = 8.0 μg/ml).","Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31964790/),[μg] / [ml],3.05,253067,DB01001,Salbutamol
,31964790,minimum sputum concentration [C min],"The average minimum concentration of vancomycin in sputum remained above the usual MIC values for MRSA for up to 24 h (minimum sputum concentration [C min], 32-mg dose = 3.05 μg/ml, 80-mg dose = 8.0 μg/ml).","Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31964790/),[μg] / [ml],8.0,253068,DB01001,Salbutamol
,31964790,systemic absorption,"In conclusion, AeroVanc was well tolerated and achieved high levels in sputum with a mean systemic absorption of 49%, making it a potential therapeutic strategy for respiratory infection with MRSA.","Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31964790/),%,49,253069,DB01001,Salbutamol
,9001926,Cmax,"The mean pharmacokinetic results for MDI and nebulizer solution were, respectively: Cmax = 7.59 ng.",Equivalence of pharmacokinetic characteristics and bronchodilating effect between two combined formulations of nedocromil sodium and salbutamol: MDI and nebulizer solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9001926/),ng,7.59,260105,DB01001,Salbutamol
,9001926,tmax,"ml-1 +/- 5.22 (p = 0.36), tmax = 0.21 hour +/- 0.08 and 0.28 hour +/- 0.14 (p = 0.19), AUCzero-->infinity = 6.28 ng.",Equivalence of pharmacokinetic characteristics and bronchodilating effect between two combined formulations of nedocromil sodium and salbutamol: MDI and nebulizer solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9001926/),h,0.21,260106,DB01001,Salbutamol
,9001926,tmax,"ml-1 +/- 5.22 (p = 0.36), tmax = 0.21 hour +/- 0.08 and 0.28 hour +/- 0.14 (p = 0.19), AUCzero-->infinity = 6.28 ng.",Equivalence of pharmacokinetic characteristics and bronchodilating effect between two combined formulations of nedocromil sodium and salbutamol: MDI and nebulizer solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9001926/),h,0.28,260107,DB01001,Salbutamol
,9001926,AUCzero-->infinity,"ml-1 +/- 5.22 (p = 0.36), tmax = 0.21 hour +/- 0.08 and 0.28 hour +/- 0.14 (p = 0.19), AUCzero-->infinity = 6.28 ng.",Equivalence of pharmacokinetic characteristics and bronchodilating effect between two combined formulations of nedocromil sodium and salbutamol: MDI and nebulizer solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9001926/),ng,6.28,260108,DB01001,Salbutamol
,8779143,maximum plasma salbutamol concentration,"The maximum plasma salbutamol concentration (mean Cmax) and time to maximum concentration (median Tmax) were: Ventolin (2.93 ng/ml, 10 minutes), Salbulin (3.01 ng/ml, 10 minutes), Salamol (3.33 ng/ml, 10 minutes).",Lung bioavailability of generic and innovator salbutamol metered dose inhalers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8779143/),[ng] / [ml],2.93,260391,DB01001,Salbutamol
,8779143,maximum plasma salbutamol concentration,"The maximum plasma salbutamol concentration (mean Cmax) and time to maximum concentration (median Tmax) were: Ventolin (2.93 ng/ml, 10 minutes), Salbulin (3.01 ng/ml, 10 minutes), Salamol (3.33 ng/ml, 10 minutes).",Lung bioavailability of generic and innovator salbutamol metered dose inhalers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8779143/),[ng] / [ml],3.01,260392,DB01001,Salbutamol
,8779143,time to maximum concentration,"The maximum plasma salbutamol concentration (mean Cmax) and time to maximum concentration (median Tmax) were: Ventolin (2.93 ng/ml, 10 minutes), Salbulin (3.01 ng/ml, 10 minutes), Salamol (3.33 ng/ml, 10 minutes).",Lung bioavailability of generic and innovator salbutamol metered dose inhalers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8779143/),[ng] / [ml],2.93,260393,DB01001,Salbutamol
,8779143,time to maximum concentration,"The maximum plasma salbutamol concentration (mean Cmax) and time to maximum concentration (median Tmax) were: Ventolin (2.93 ng/ml, 10 minutes), Salbulin (3.01 ng/ml, 10 minutes), Salamol (3.33 ng/ml, 10 minutes).",Lung bioavailability of generic and innovator salbutamol metered dose inhalers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8779143/),[ng] / [ml],3.01,260394,DB01001,Salbutamol
,8779143,time to maximum concentration,"The maximum plasma salbutamol concentration (mean Cmax) and time to maximum concentration (median Tmax) were: Ventolin (2.93 ng/ml, 10 minutes), Salbulin (3.01 ng/ml, 10 minutes), Salamol (3.33 ng/ml, 10 minutes).",Lung bioavailability of generic and innovator salbutamol metered dose inhalers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8779143/),[ng] / [ml],3.33,260395,DB01001,Salbutamol
,7905380,plasma t1/2,"The plasma t1/2, after intravenous administration, was 5 hr in rats and 2 hr in dogs.",Disposition of salmeterol xinafoate in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),h,5,260650,DB01001,Salbutamol
,7905380,plasma t1/2,"The plasma t1/2, after intravenous administration, was 5 hr in rats and 2 hr in dogs.",Disposition of salmeterol xinafoate in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),h,2,260651,DB01001,Salbutamol
,7905380,volume of distribution,The volume of distribution of salmeterol was significantly greater than total body water in both rats (40 liters/kg) and dogs (6 liters/kg) and indicated high tissue uptake of the compound.,Disposition of salmeterol xinafoate in laboratory animals and humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),[l] / [kg],40,260652,DB01001,Salbutamol
,7905380,volume of distribution,The volume of distribution of salmeterol was significantly greater than total body water in both rats (40 liters/kg) and dogs (6 liters/kg) and indicated high tissue uptake of the compound.,Disposition of salmeterol xinafoate in laboratory animals and humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),[l] / [kg],6,260653,DB01001,Salbutamol
,7905380,Plasma clearance,Plasma clearance was high in rats (95 ml/min/kg) and dogs (30 ml/min/kg).,Disposition of salmeterol xinafoate in laboratory animals and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),[ml] / [kg·min],95,260654,DB01001,Salbutamol
,7905380,Plasma clearance,Plasma clearance was high in rats (95 ml/min/kg) and dogs (30 ml/min/kg).,Disposition of salmeterol xinafoate in laboratory animals and humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),[ml] / [kg·min],30,260655,DB01001,Salbutamol
,7905380,Biliary excretion,"Biliary excretion in rats and dogs accounted for 53% (0-27 hr) and 40% (0-8 hr) of an oral dose, respectively, indicating good absorption across the gastrointestinal tract.",Disposition of salmeterol xinafoate in laboratory animals and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),%,53,260656,DB01001,Salbutamol
,7905380,Biliary excretion,"Biliary excretion in rats and dogs accounted for 53% (0-27 hr) and 40% (0-8 hr) of an oral dose, respectively, indicating good absorption across the gastrointestinal tract.",Disposition of salmeterol xinafoate in laboratory animals and humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905380/),%,40,260657,DB01001,Salbutamol
,28061018,concentrations,"Initial mean ± 95%CI (R)- and (S)-salbutamol PELF concentrations were 389 ± 189 ng g-1 and 378 ± 177 ng g-1 respectively, and both reduced approximately 50% by 15 min.",Bronchopulmonary pharmacokinetics of (R)-salbutamol and (S)-salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28061018/),[ng] / [g],389,262527,DB01001,Salbutamol
,28061018,concentrations,"Initial mean ± 95%CI (R)- and (S)-salbutamol PELF concentrations were 389 ± 189 ng g-1 and 378 ± 177 ng g-1 respectively, and both reduced approximately 50% by 15 min.",Bronchopulmonary pharmacokinetics of (R)-salbutamol and (S)-salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28061018/),[ng] / [g],378,262528,DB01001,Salbutamol
,28061018,central lung levels,Mean ± 95%CI central lung levels of drug were higher than peripheral lung tissue for both (R)-salbutamol (875 ± 945 vs. 49.5 ± 12 ng g-1 ) and (S)-salbutamol (877 ± 955 vs. 50.9 ± 12 ng g-1 ) respectively.,Bronchopulmonary pharmacokinetics of (R)-salbutamol and (S)-salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28061018/),[ng] / [g],875,262529,DB01001,Salbutamol
,28061018,central lung levels,Mean ± 95%CI central lung levels of drug were higher than peripheral lung tissue for both (R)-salbutamol (875 ± 945 vs. 49.5 ± 12 ng g-1 ) and (S)-salbutamol (877 ± 955 vs. 50.9 ± 12 ng g-1 ) respectively.,Bronchopulmonary pharmacokinetics of (R)-salbutamol and (S)-salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28061018/),[ng] / [g],49.5,262530,DB01001,Salbutamol
,28061018,central lung levels,Mean ± 95%CI central lung levels of drug were higher than peripheral lung tissue for both (R)-salbutamol (875 ± 945 vs. 49.5 ± 12 ng g-1 ) and (S)-salbutamol (877 ± 955 vs. 50.9 ± 12 ng g-1 ) respectively.,Bronchopulmonary pharmacokinetics of (R)-salbutamol and (S)-salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28061018/),[ng] / [g],877,262531,DB01001,Salbutamol
,28061018,central lung levels,Mean ± 95%CI central lung levels of drug were higher than peripheral lung tissue for both (R)-salbutamol (875 ± 945 vs. 49.5 ± 12 ng g-1 ) and (S)-salbutamol (877 ± 955 vs. 50.9 ± 12 ng g-1 ) respectively.,Bronchopulmonary pharmacokinetics of (R)-salbutamol and (S)-salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28061018/),[ng] / [g],50.9,262532,DB01001,Salbutamol
,22498110,trough FE,"All once-daily doses of GSK573719 significantly increased trough FEV(1) at Day 15 with improvements ranging from 95 to 186 mL over placebo (p ≤ 0.006), from 79 to 172 mL with twice-daily dosing (p ≤ 0.03), and 105 mL with tiotropium (p = 0.003).","A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22498110/),ml,95 to 186,263802,DB01001,Salbutamol
,22498110,trough FE,"All once-daily doses of GSK573719 significantly increased trough FEV(1) at Day 15 with improvements ranging from 95 to 186 mL over placebo (p ≤ 0.006), from 79 to 172 mL with twice-daily dosing (p ≤ 0.03), and 105 mL with tiotropium (p = 0.003).","A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22498110/),ml,79 to 172,263803,DB01001,Salbutamol
,22498110,trough FE,"All once-daily doses of GSK573719 significantly increased trough FEV(1) at Day 15 with improvements ranging from 95 to 186 mL over placebo (p ≤ 0.006), from 79 to 172 mL with twice-daily dosing (p ≤ 0.03), and 105 mL with tiotropium (p = 0.003).","A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22498110/),ml,105,263804,DB01001,Salbutamol
,18403223,FEV(1),Mean+/-SD baseline FEV(1)=1.4+/-0.5 L (49+/-12% predicted).,Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18403223/),l,1.4,267555,DB01001,Salbutamol
,18403223,area under the curve from 0 to 6h,"IB+ALB resulted in significantly greater improvements over ALB in the average improvement over baseline in FEV(1) as approximated from the area under the curve from 0 to 6h after drug administration (72 ml, p<0.01) and mean peak FEV(1) response (55 ml, p<0.01) as well as higher FEV(1) responses at individual time points from 0.5 to 6h postdose (p<0.01 for all).",Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18403223/),ml,72,267556,DB01001,Salbutamol
,18403223,peak,"IB+ALB resulted in significantly greater improvements over ALB in the average improvement over baseline in FEV(1) as approximated from the area under the curve from 0 to 6h after drug administration (72 ml, p<0.01) and mean peak FEV(1) response (55 ml, p<0.01) as well as higher FEV(1) responses at individual time points from 0.5 to 6h postdose (p<0.01 for all).",Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18403223/),ml,55,267557,DB01001,Salbutamol
,18403223,Time to onset of response,"Time to onset of response was similar between groups but time to peak and duration of response were longer with IB+ALB versus ALB (120 versus 60 min and 245 versus 106 min, respectively).",Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18403223/),min,120,267558,DB01001,Salbutamol
,18403223,Time to onset of response,"Time to onset of response was similar between groups but time to peak and duration of response were longer with IB+ALB versus ALB (120 versus 60 min and 245 versus 106 min, respectively).",Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18403223/),min,60,267559,DB01001,Salbutamol
,18403223,time to peak,"Time to onset of response was similar between groups but time to peak and duration of response were longer with IB+ALB versus ALB (120 versus 60 min and 245 versus 106 min, respectively).",Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18403223/),min,120,267560,DB01001,Salbutamol
,18403223,time to peak,"Time to onset of response was similar between groups but time to peak and duration of response were longer with IB+ALB versus ALB (120 versus 60 min and 245 versus 106 min, respectively).",Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18403223/),min,60,267561,DB01001,Salbutamol
,18403223,duration of response,"Time to onset of response was similar between groups but time to peak and duration of response were longer with IB+ALB versus ALB (120 versus 60 min and 245 versus 106 min, respectively).",Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18403223/),min,245,267562,DB01001,Salbutamol
,18403223,duration of response,"Time to onset of response was similar between groups but time to peak and duration of response were longer with IB+ALB versus ALB (120 versus 60 min and 245 versus 106 min, respectively).",Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18403223/),min,106,267563,DB01001,Salbutamol
,8016791,urinary excretion,"The mean (SD) urinary excretion of salbutamol 30 minutes after inhalation using the MDI alone and with the Volumatic, Bricanyl Spacer, Nebuhaler, and open mouth technique was 2.83 (0.78)%, 3.37 (0.69)%, 4.09 (0.91)%, 4.34 (1.60)%, and 3.49 (0.98)%, respectively, expressed as a percentage of the nominal dose.",Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016791/),%,2.83,270427,DB01001,Salbutamol
,8016791,urinary excretion,"The mean (SD) urinary excretion of salbutamol 30 minutes after inhalation using the MDI alone and with the Volumatic, Bricanyl Spacer, Nebuhaler, and open mouth technique was 2.83 (0.78)%, 3.37 (0.69)%, 4.09 (0.91)%, 4.34 (1.60)%, and 3.49 (0.98)%, respectively, expressed as a percentage of the nominal dose.",Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016791/),%,3.37,270428,DB01001,Salbutamol
,8016791,urinary excretion,"The mean (SD) urinary excretion of salbutamol 30 minutes after inhalation using the MDI alone and with the Volumatic, Bricanyl Spacer, Nebuhaler, and open mouth technique was 2.83 (0.78)%, 3.37 (0.69)%, 4.09 (0.91)%, 4.34 (1.60)%, and 3.49 (0.98)%, respectively, expressed as a percentage of the nominal dose.",Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016791/),%,4.09,270429,DB01001,Salbutamol
,8016791,urinary excretion,"The mean (SD) urinary excretion of salbutamol 30 minutes after inhalation using the MDI alone and with the Volumatic, Bricanyl Spacer, Nebuhaler, and open mouth technique was 2.83 (0.78)%, 3.37 (0.69)%, 4.09 (0.91)%, 4.34 (1.60)%, and 3.49 (0.98)%, respectively, expressed as a percentage of the nominal dose.",Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016791/),%,4.34,270430,DB01001,Salbutamol
,8016791,urinary excretion,"The mean (SD) urinary excretion of salbutamol 30 minutes after inhalation using the MDI alone and with the Volumatic, Bricanyl Spacer, Nebuhaler, and open mouth technique was 2.83 (0.78)%, 3.37 (0.69)%, 4.09 (0.91)%, 4.34 (1.60)%, and 3.49 (0.98)%, respectively, expressed as a percentage of the nominal dose.",Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016791/),%,3.49,270431,DB01001,Salbutamol
,8016791,24 hour,"The mean (SD) 24 hour urinary excretion of salbutamol and its metabolites was 26.6 (6.79), 27.0 (7.95), and 55.6 (9.74)% of the salbutamol dose for the Volumatic, Nebuhaler, and MDI, respectively.",Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016791/),%,26.6,270432,DB01001,Salbutamol
,8016791,urinary excretion,"The mean (SD) 24 hour urinary excretion of salbutamol and its metabolites was 26.6 (6.79), 27.0 (7.95), and 55.6 (9.74)% of the salbutamol dose for the Volumatic, Nebuhaler, and MDI, respectively.",Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016791/),%,26.6,270433,DB01001,Salbutamol
,8016791,urinary excretion,"The mean (SD) 24 hour urinary excretion of salbutamol and its metabolites was 26.6 (6.79), 27.0 (7.95), and 55.6 (9.74)% of the salbutamol dose for the Volumatic, Nebuhaler, and MDI, respectively.",Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016791/),%,27.0,270434,DB01001,Salbutamol
,8016791,urinary excretion,"The mean (SD) 24 hour urinary excretion of salbutamol and its metabolites was 26.6 (6.79), 27.0 (7.95), and 55.6 (9.74)% of the salbutamol dose for the Volumatic, Nebuhaler, and MDI, respectively.",Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016791/),%,55.6,270435,DB01001,Salbutamol
,11294367,pulse rate,"With the exception of a higher pulse rate after repeat administration of salmeterol [66.2 beats per minute (bpm) versus 63.6 bpm], there were no significant differences between the single-dose and repeat-dose salmeterol groups.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),[beats·min] / [bpm],66.2,273152,DB01001,Salbutamol
,11294367,pulse rate,"With the exception of a higher pulse rate after repeat administration of salmeterol [66.2 beats per minute (bpm) versus 63.6 bpm], there were no significant differences between the single-dose and repeat-dose salmeterol groups.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),bpm,63.6,273153,DB01001,Salbutamol
,11294367,excretion,"Fluticasone propionate reduced 24-h urinary cortisol excretion (22.4 microg compared with 48.6 microg with placebo), but this was unaffected by the co-administration of salmeterol.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),μg,22.4,273154,DB01001,Salbutamol
,11294367,excretion,"Fluticasone propionate reduced 24-h urinary cortisol excretion (22.4 microg compared with 48.6 microg with placebo), but this was unaffected by the co-administration of salmeterol.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),μg,48.6,273155,DB01001,Salbutamol
